|
humans |
100 |
|
male |
81 |
|
female |
73 |
|
adult |
72 |
|
middle aged |
68 |
|
aged |
47 |
|
reverse transcriptase polymerase chain reaction |
28 |
|
animals |
27 |
|
adolescent |
25 |
|
aged, 80 and over |
25 |
|
bone marrow transplantation |
23 |
|
retrospective studies |
23 |
|
treatment outcome |
23 |
|
medical sciences |
22 |
|
polymerase chain reaction |
22 |
|
prognosis |
22 |
|
mutation |
19 |
|
recurrence |
19 |
|
cohort studies |
18 |
|
arsenic trioxide |
17 |
|
base sequence |
17 |
|
cell line, tumor |
17 |
|
dna methylation |
17 |
|
follow-up studies |
17 |
|
mice |
17 |
|
mice, nude |
17 |
|
transfection |
17 |
|
β-catenin |
17 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
16 |
|
fatal outcome |
16 |
|
hematopoietic stem cell transplantation - adverse effects |
16 |
|
immunophenotyping |
16 |
|
neoplasm proteins - genetics |
16 |
|
translocation, genetic |
16 |
|
acute disease |
15 |
|
acute myeloid leukemia |
15 |
|
child |
15 |
|
flow cytometry |
15 |
|
hepatocellular carcinoma |
15 |
|
peptidyl-prolyl-isomerase |
15 |
|
pin1 |
15 |
|
chromosome aberrations |
14 |
|
hematopoietic stem cell transplantation |
14 |
|
immunohistochemistry |
14 |
|
in situ hybridization, fluorescence |
14 |
|
karyotyping |
14 |
|
polymerase chain reaction - methods |
14 |
|
prevalence |
14 |
|
prospective studies |
14 |
|
dna primers |
13 |
|
risk factors |
13 |
|
transcription factors - genetics |
13 |
|
cell differentiation |
12 |
|
child, preschool |
12 |
|
chinese |
12 |
|
disease progression |
12 |
|
dna-binding proteins - genetics |
12 |
|
leukaemia |
12 |
|
promoter regions, genetic |
12 |
|
remission induction |
12 |
|
rna, messenger - metabolism |
12 |
|
trans-activators - genetics |
12 |
|
transplantation, homologous |
12 |
|
acute promyelocytic leukemia |
11 |
|
asian continental ancestry group |
11 |
|
beta catenin |
11 |
|
bone marrow |
11 |
|
bone marrow transplantation - adverse effects |
11 |
|
carcinoma, hepatocellular - etiology - genetics - metabolism |
11 |
|
case-control studies |
11 |
|
chronic disease |
11 |
|
cyclin d1 - biosynthesis - genetics |
11 |
|
cytoskeletal proteins - genetics |
11 |
|
disease-free survival |
11 |
|
essential thrombocythemia |
11 |
|
gene expression regulation, neoplastic |
11 |
|
immunosuppression - adverse effects |
11 |
|
incidence |
11 |
|
magnetic resonance imaging |
11 |
|
molecular sequence data |
11 |
|
myelofibrosis |
11 |
|
neoplasm transplantation |
11 |
|
peptidylprolyl isomerase - biosynthesis - genetics |
11 |
|
survival analysis |
11 |
|
transplantation, heterologous |
11 |
|
young adult |
11 |
|
alemtuzumab |
10 |
|
antiviral agents - therapeutic use |
10 |
|
biopsy |
10 |
|
case report |
10 |
|
cell count |
10 |
|
cell proliferation |
10 |
|
china |
10 |
|
dna, viral - analysis |
10 |
|
infant |
10 |
|
severity of illness index |
10 |
|
amino acid motifs |
9 |
|
antigens, cd44 - genetics - metabolism |
9 |
|
bone marrow - pathology |
9 |
|
cell line |
9 |
|
cyclin d1 - genetics |
9 |
|
diagnosis, differential |
9 |
|
epstein barr virus |
9 |
|
hematopoietic stem cell transplantation - adverse effects - methods |
9 |
|
immunoglobulin heavy chains - genetics |
9 |
|
immunosuppressive agents - therapeutic use |
9 |
|
killer cells, natural - metabolism |
9 |
|
lymphoma |
9 |
|
lymphoma, follicular - genetics - pathology |
9 |
|
lymphoma, large b-cell, diffuse - genetics - pathology |
9 |
|
nuclear proteins - biosynthesis - genetics |
9 |
|
polycythemia vera |
9 |
|
promoter regions, genetic - genetics |
9 |
|
proto-oncogene proteins - genetics |
9 |
|
reference values |
9 |
|
reproducibility of results |
9 |
|
stomach neoplasms - genetics - pathology |
9 |
|
survival rate |
9 |
|
time factors |
9 |
|
tomography, x-ray computed |
9 |
|
transcriptional activation |
9 |
|
tumor cells, cultured |
9 |
|
antigens, cd - blood |
8 |
|
antineoplastic agents - therapeutic use |
8 |
|
china - epidemiology |
8 |
|
clofarabine |
8 |
|
clone cells |
8 |
|
cytarabine |
8 |
|
cytomegalovirus |
8 |
|
dna, viral - blood |
8 |
|
dose-response relationship, drug |
8 |
|
gastroenterology |
8 |
|
graft versus host disease |
8 |
|
hematology |
8 |
|
herpesvirus 4, human - genetics |
8 |
|
histocompatibility testing |
8 |
|
hong kong - epidemiology |
8 |
|
in situ hybridization |
8 |
|
indolent lymphoma |
8 |
|
living donors |
8 |
|
neoplasm, residual |
8 |
|
nf-kappa b - metabolism |
8 |
|
nk/t-cell lymphoma |
8 |
|
nucleic acid hybridization |
8 |
|
pet/ct |
8 |
|
proto-oncogene proteins c-bcl-6 |
8 |
|
relapse |
8 |
|
rituximab |
8 |
|
sensitivity and specificity |
8 |
|
sex factors |
8 |
|
stem cell transplantation - adverse effects |
8 |
|
transcription, genetic |
8 |
|
tretinoin - therapeutic use |
8 |
|
viral load |
8 |
|
virus activation |
8 |
|
acute lymphoblastic leukemia |
7 |
|
adaptor proteins, signal transducing |
7 |
|
adiponectin |
7 |
|
adiponectin - blood - chemistry - genetics |
7 |
|
adiponectin oligomeric form |
7 |
|
amino acid substitution |
7 |
|
antibiotic prophylaxis |
7 |
|
asia |
7 |
|
asian continental ancestry group - genetics |
7 |
|
beta catenin - genetics |
7 |
|
blotting, southern |
7 |
|
bone marrow cells - pathology |
7 |
|
cancer regression |
7 |
|
carcinoma, hepatocellular - genetics |
7 |
|
cell cycle proteins |
7 |
|
cell division |
7 |
|
chronic hepatitis b |
7 |
|
diffuse large b cell lymphoma |
7 |
|
enzyme-linked immunosorbent assay |
7 |
|
epstein-barr virus |
7 |
|
fludarabine |
7 |
|
gene expression regulation, leukemic |
7 |
|
gene expression regulation, neoplastic - genetics |
7 |
|
gene rearrangement |
7 |
|
haematopoietic stem cell transplantation |
7 |
|
hepatitis b surface antigens - blood |
7 |
|
hepatitis b virus |
7 |
|
hepatitis b, chronic - complications - drug therapy - pathology |
7 |
|
hong kong |
7 |
|
killer cells, natural |
7 |
|
killer cells, natural - immunology - pathology |
7 |
|
killer cells, natural - pathology |
7 |
|
lamivudine |
7 |
|
leukemia, myeloid, acute - genetics |
7 |
|
liver - metabolism |
7 |
|
liver cirrhosis |
7 |
|
liver cirrhosis - blood - metabolism - pathology - virology |
7 |
|
liver neoplasms - genetics |
7 |
|
lymphoma - epidemiology - genetics |
7 |
|
mantle cell lymphoma |
7 |
|
mediastinal neoplasms - drug therapy - pathology |
7 |
|
mice, inbred balb c |
7 |
|
mitoxantrone |
7 |
|
molecular weight |
7 |
|
multiple myeloma - therapy |
7 |
|
nasopharyngeal carcinoma |
7 |
|
neoplasm proteins - analysis |
7 |
|
oncology |
7 |
|
oral arsenic trioxide |
7 |
|
p16 |
7 |
|
pegylated interferon alfa-2a |
7 |
|
pembrolizumab |
7 |
|
peptidylprolyl isomerase - genetics |
7 |
|
positron-emission tomography |
7 |
|
post-transplantation lymphoproliferative disease |
7 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics |
7 |
|
prophylaxis |
7 |
|
refractory |
7 |
|
rna interference |
7 |
|
rna, neoplasm - genetics |
7 |
|
salvage therapy |
7 |
|
serine |
7 |
|
solid organ transplantation |
7 |
|
stomach neoplasms - epidemiology - genetics |
7 |
|
sustained virological response |
7 |
|
transfection - methods |
7 |
|
transplantation, autologous |
7 |
|
treatment |
7 |
|
up-regulation - genetics |
7 |
|
urine - virology |
7 |
|
acute promyelocytic leukaemia |
6 |
|
age factors |
6 |
|
antibodies, monoclonal - administration & dosage |
6 |
|
antibodies, monoclonal, humanized |
6 |
|
antibodies, monoclonal, murine-derived |
6 |
|
antineoplastic agents - administration & dosage - adverse effects |
6 |
|
antineoplastic agents - administration and dosage - adverse effects |
6 |
|
arsenicals - therapeutic use |
6 |
|
bcl-x protein - genetics - metabolism |
6 |
|
benzenesulfonates - administration and dosage - adverse effects |
6 |
|
bk virus - isolation & purification - physiology |
6 |
|
blood transfusion |
6 |
|
bone marrow transplantation - methods |
6 |
|
breakthrough invasive fungal infections |
6 |
|
bronchiolitis obliterans syndrome |
6 |
|
candida tropicalis fungaemia |
6 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - virology |
6 |
|
carcinoma, squamous cell - genetics |
6 |
|
carcinoma, squamous cell - genetics - pathology |
6 |
|
carrier proteins - biosynthesis - genetics |
6 |
|
cd56 |
6 |
|
cell nucleus - genetics - pathology |
6 |
|
cell transformation, neoplastic - genetics - metabolism |
6 |
|
chronic lymphocytic leukemia |
6 |
|
cyclophosphamide |
6 |
|
cyclophosphamide - therapeutic use |
6 |
|
cytogenetics |
6 |
|
dexamethasone - administration & dosage |
6 |
|
dexamethasone - administration & dosage - adverse effects |
6 |
|
dna, complementary - genetics |
6 |
|
drug resistance, neoplasm - drug effects - genetics |
6 |
|
echinocandin |
6 |
|
fluorodeoxyglucose f18 - diagnostic use |
6 |
|
graft survival |
6 |
|
graft vs host disease - drug therapy - etiology - pathology |
6 |
|
graft vs host disease - epidemiology |
6 |
|
haematological malignancies |
6 |
|
hepatitis b - complications - genetics - metabolism - pathology - virology |
6 |
|
hepatitis b surface antigens - immunology |
6 |
|
hla |
6 |
|
hong kong chinese |
6 |
|
hydroxyurea |
6 |
|
jak2 |
6 |
|
leukemia, myelogenous, chronic, bcr-abl positive - therapy |
6 |
|
leukemia, myeloid, acute - drug therapy - enzymology - genetics - pathology |
6 |
|
leukemia, promyelocytic, acute - drug therapy |
6 |
|
liver neoplasms - genetics - metabolism - pathology - virology |
6 |
|
liver neoplasms, experimental - metabolism - pathology - virology |
6 |
|
lung function decline |
6 |
|
lymphoma - genetics |
6 |
|
lymphoma, large b-cell, diffuse - drug therapy - pathology |
6 |
|
lymphoma, t-cell - genetics - immunology - pathology |
6 |
|
lymphoma, t-cell - genetics - metabolism |
6 |
|
medicine & public health |
6 |
|
methotrexate |
6 |
|
mitoxantrone - administration & dosage |
6 |
|
mitoxantrone - administration & dosage - adverse effects |
6 |
|
multivariate analysis |
6 |
|
neoplasm staging |
6 |
|
nk-cell lymphoma |
6 |
|
nose |
6 |
|
nose neoplasms - genetics - metabolism |
6 |
|
oxides - therapeutic use |
6 |
|
peptidylprolyl isomerase - genetics - metabolism |
6 |
|
phosphorylation |
6 |
|
polyploidy |
6 |
|
prognostic factors |
6 |
|
proline |
6 |
|
protein binding |
6 |
|
proto-oncogene proteins c-myc - genetics - metabolism |
6 |
|
pure red cell aplasia |
6 |
|
rassf1a |
6 |
|
reverse transcriptase polymerase chain reaction - methods |
6 |
|
sorafenib |
6 |
|
staged approach |
6 |
|
stem cell transplantation |
6 |
|
steroids |
6 |
|
stomach neoplasms - genetics |
6 |
|
tissue donors |
6 |
|
trans-activators - genetics - metabolism |
6 |
|
transcription factor rela - genetics - metabolism |
6 |
|
transplantation, homologous - adverse effects |
6 |
|
tumor markers, biological - blood |
6 |
|
up-regulation |
6 |
|
vidarabine - administration & dosage - adverse effects - analogs & derivatives |
6 |
|
vidarabine - administration & dosage - analogs & derivatives |
6 |
|
vtd |
6 |
|
acquired immunodeficiency syndrome - complications - diagnosis |
5 |
|
administration, oral |
5 |
|
adrenal cortex hormones - therapeutic use |
5 |
|
aldehyde dehydrogenase - analysis |
5 |
|
allogeneic stem cell transplantation |
5 |
|
aml |
5 |
|
amyloidosis, familial - ethnology - genetics - pathology |
5 |
|
aneuploidy |
5 |
|
animals, newborn |
5 |
|
anti-bacterial agents - pharmacology - therapeutic use |
5 |
|
antifungal drug |
5 |
|
antigens, cd34 - analysis |
5 |
|
antigens, cd56 - metabolism |
5 |
|
antineoplastic agents, alkylating - adverse effects - therapeutic use |
5 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - adverse effects - therapeutic use |
5 |
|
antineoplastic combined chemotherapy protocols - adverse effects - therapeutic use |
5 |
|
apoptosis - drug effects |
5 |
|
arsenicals - administration & dosage |
5 |
|
arteriosclerosis - etiology - pathology - ultrasonography |
5 |
|
aspergillosis - etiology |
5 |
|
azacitidine |
5 |
|
azithromycin |
5 |
|
bacteremia - complications - epidemiology - etiology |
5 |
|
bacteria - isolation & purification |
5 |
|
bk virus - isolation & purification |
5 |
|
blood platelets - microbiology |
5 |
|
bone marrow transplantation - methods - physiology |
5 |
|
boronic acids - therapeutic use |
5 |
|
bronchiolitis obliterans syndrome (bos) |
5 |
|
cancer recurrence |
5 |
|
carcinoma - blood - diagnosis - genetics |
5 |
|
carotid arteries - pathology - ultrasonography |
5 |
|
catheterization - adverse effects |
5 |
|
chromosome deletion |
5 |
|
chromosomes, human - ultrastructure |
5 |
|
chromosomes, human, pair 11 |
5 |
|
chromosomes, human, pair 15 |
5 |
|
chromosomes, human, pair 21 |
5 |
|
chromosomes, human, pair 8 |
5 |
|
ciprofloxacin - pharmacology - therapeutic use |
5 |
|
cryptococcosis - diagnosis - etiology |
5 |
|
cyclin-dependent kinase inhibitor p15 |
5 |
|
cyclosporine - therapeutic use |
5 |
|
cytarabine - administration & dosage |
5 |
|
cytokines - blood - genetics - metabolism |
5 |
|
diffuse large b-cell lymphoma |
5 |
|
dlbcl |
5 |
|
dli |
5 |
|
dna mutational analysis |
5 |
|
dna-binding proteins - biosynthesis - genetics |
5 |
|
down-regulation - genetics |
5 |
|
drug evaluation |
5 |
|
electrophysiologic techniques, cardiac |
5 |
|
emergencies |
5 |
|
endothelial cells - pathology |
5 |
|
endothelium, vascular - pathology - ultrastructure |
5 |
|
epithelial cells - metabolism - pathology |
5 |
|
esophageal neoplasms - genetics - pathology |
5 |
|
exome sequencing |
5 |
|
familial transthyretin amyloidosis |
5 |
|
fever - etiology - therapy |
5 |
|
fish |
5 |
|
flt3-itd |
5 |
|
fnd |
5 |
|
fusion proteins, bcr-abl - genetics |
5 |
|
gene expression profiling |
5 |
|
gene frequency |
5 |
|
gene rearrangement, delta-chain t-cell antigen receptor |
5 |
|
genes, p16 |
5 |
|
genetic mutations |
5 |
|
genetic predisposition to disease |
5 |
|
genotype |
5 |
|
helicobacter pylori |
5 |
|
hematologic neoplasms - complications - therapy |
5 |
|
hematopoietic sct (hsct) |
5 |
|
hepatitis b - complications - etiology |
5 |
|
hepatitis b antibodies - blood |
5 |
|
hodgkin disease - drug therapy - pathology |
5 |
|
hodgkin lymphoma |
5 |
|
hsct |
5 |
|
hypermethylation |
5 |
|
idiopathic thrombocytopenic purpura |
5 |
|
immunocompromised host |
5 |
|
immunoglobulins - chemistry |
5 |
|
immunosuppressive agents |
5 |
|
immunosuppressive agents - adverse effects - therapeutic use |
5 |
|
ischaemic myocardium |
5 |
|
keratins - analysis |
5 |
|
kidney transplantation |
5 |
|
l-asparaginase |
5 |
|
leukemia |
5 |
|
leukemia - therapy |
5 |
|
leukemia, large granular lymphocytic - complications - drug therapy |
5 |
|
leukemia, myeloid - diagnosis - pathology |
5 |
|
leukemia, myeloid - genetics |
5 |
|
leukemia, myeloid, acute - genetics - pathology |
5 |
|
leukemia, prolymphocytic, t-cell - drug therapy - ethnology |
5 |
|
leukocyte count |
5 |
|
leukocytes, mononuclear - physiology |
5 |
|
liver diseases - drug therapy - etiology |
5 |
|
liver failure - etiology - surgery |
5 |
|
liver gvhd |
5 |
|
liver transplantation |
5 |
|
living related donor |
5 |
|
lmp1 |
5 |
|
low‐dose |
5 |
|
lymphatic diseases - diagnosis - etiology |
5 |
|
lymphocyte transfusion - adverse effects |
5 |
|
lymphoma - diagnosis |
5 |
|
lymphoma - therapy |
5 |
|
lymphoma, b-cell - drug therapy - ethnology |
5 |
|
lymphoma, large b-cell, diffuse - drug therapy |
5 |
|
lymphoma, non-hodgkin - drug therapy - ethnology |
5 |
|
lymphoma, t-cell - epidemiology - pathology - therapy |
5 |
|
maintenance |
5 |
|
marrow transplantation |
5 |
|
mature t-cell lymphoma |
5 |
|
microenvironment |
5 |
|
microrna |
5 |
|
microspheres |
5 |
|
microtubules |
5 |
|
microtubules - metabolism - pathology |
5 |
|
mitosis |
5 |
|
mucosa-associated lymphoid tissue |
5 |
|
mycobacterium infections - etiology - microbiology |
5 |
|
myeloablative agonists - therapeutic use |
5 |
|
myelodysplastic syndromes - genetics |
5 |
|
myelodysplastic syndromes - genetics - metabolism |
5 |
|
myocardial ischemia - physiopathology |
5 |
|
myocardial revascularization - methods |
5 |
|
myocardium - metabolism |
5 |
|
nasal lymphoma |
5 |
|
nasopharyngeal epithelial cells |
5 |
|
nasopharyngeal neoplasms - blood - diagnosis - genetics |
5 |
|
natural killer cell lymphoma |
5 |
|
neoplastic stem cells - pathology |
5 |
|
neovascularization |
5 |
|
neovascularization, physiologic |
5 |
|
next-generation sequencing |
5 |
|
nf-κb |
5 |
|
nivolumab |
5 |
|
nk cell lymphoma |
5 |
|
non-gastric marginal zone lymphoma |
5 |
|
non-hodgkin's lymphoma |
5 |
|
nontuberculous mycobacterium |
5 |
|
orthotopic liver transplantation |
5 |
|
oxides - administration & dosage |
5 |
|
p15 |
5 |
|
papillomaviridae - genetics |
5 |
|
papillomavirus e7 proteins |
5 |
|
paracrine communication |
5 |
|
pcr |
5 |
|
philadelphia chromosome |
5 |
|
platelet transfusion - adverse effects |
5 |
|
polymorphism, genetic |
5 |
|
polyoma bk virus |
5 |
|
polyomavirus infections - prevention & control - virology |
5 |
|
post-transplant lymphoproliferative disorders |
5 |
|
prealbumin - genetics |
5 |
|
precursor cell lymphoblastic leukemia-lymphoma - pathology |
5 |
|
prednisolone - therapeutic use |
5 |
|
pregnancy |
5 |
|
primary |
5 |
|
proportional hazards models |
5 |
|
protein transport |
5 |
|
protein-losing enteropathies - drug therapy - etiology |
5 |
|
respiratory tract infections - etiology - microbiology |
5 |
|
restriction mapping |
5 |
|
secondary |
5 |
|
sequence homology, nucleic acid |
5 |
|
smile |
5 |
|
splenectomy |
5 |
|
splenic marginal zone lymphoma |
5 |
|
splenomegaly |
5 |
|
stem cells - pathology |
5 |
|
stem cells - physiology |
5 |
|
stroke - pathology |
5 |
|
swine |
5 |
|
swine, miniature |
5 |
|
t-lymphocytes - pathology |
5 |
|
tcga |
5 |
|
the cancer genome atlas |
5 |
|
thrombocytosis - genetics |
5 |
|
transplantation conditioning |
5 |
|
treatment failure |
5 |
|
ttr gene |
5 |
|
tumor cells, cultured - chemistry - pathology |
5 |
|
tumor markers, biological - metabolism |
5 |
|
tumor suppressor |
5 |
|
tumor suppressor proteins |
5 |
|
tumor suppressor proteins - antagonists and inhibitors - biosynthesis - genetics |
5 |
|
tumor suppressor proteins - blood - genetics - metabolism |
5 |
|
tumor virus infections - prevention & control - virology |
5 |
|
tunica intima - ultrasonography |
5 |
|
tunica media - ultrasonography |
5 |
|
vascular endothelial growth factor a - metabolism |
5 |
|
ventricular function, left |
5 |
|
vincristine |
5 |
|
virus replication - drug effects |
5 |
|
acute myeloid leukemic |
4 |
|
adenoviridae - genetics - isolation & purification |
4 |
|
adenoviridae - isolation & purification |
4 |
|
adenoviridae - physiology |
4 |
|
adenoviridae infections - etiology - pathology |
4 |
|
adoptive transfer |
4 |
|
adult acute lymphoblastic leukemia |
4 |
|
alanine transaminase - blood |
4 |
|
alkaline phosphatase - blood |
4 |
|
all-trans retinoic acid |
4 |
|
alleles |
4 |
|
allogeneic bmt |
4 |
|
allogeneic bone marrow transplantation |
4 |
|
antibodies, antinuclear - analysis |
4 |
|
antibodies, monoclonal - administration & dosage - adverse effects |
4 |
|
antibodies, monoclonal - therapeutic use |
4 |
|
antibodies, neoplasm - administration & dosage - adverse effects |
4 |
|
antibodies, neoplasm - therapeutic use |
4 |
|
antigens, cd20 - metabolism |
4 |
|
antigens, cd56 - analysis |
4 |
|
antigens, cd95 - genetics - metabolism |
4 |
|
antigens, neoplasm - metabolism |
4 |
|
antigens, viral - blood |
4 |
|
antinuclear antibody |
4 |
|
apoptosis - physiology |
4 |
|
arsenicals - administration & dosage - blood - therapeutic use |
4 |
|
aspartate aminotransferases - blood |
4 |
|
autoimmune diseases - blood - complications - drug therapy - virology |
4 |
|
b cell depletion |
4 |
|
basal ganglion |
4 |
|
bilirubin - blood |
4 |
|
biological markers |
4 |
|
bk virus - genetics - isolation & purification |
4 |
|
bk virus - physiology |
4 |
|
bleomycin |
4 |
|
bmt |
4 |
|
bone marrow - pathology - physiopathology |
4 |
|
bone marrow cells |
4 |
|
bone marrow cells - drug effects - metabolism |
4 |
|
bone marrow examination - methods |
4 |
|
bone marrow transplantation - adverse effects - methods - pathology |
4 |
|
bone marrow transplantation - pathology |
4 |
|
bone marrow transplantation - statistics & numerical data |
4 |
|
busulfan - adverse effects - therapeutic use |
4 |
|
cadaver |
4 |
|
cancer prognosis |
4 |
|
cancer risk |
4 |
|
cancer staging |
4 |
|
carcinoma - blood - mortality - pathology |
4 |
|
carcinoma - genetics |
4 |
|
carrier state - epidemiology - immunology - microbiology |
4 |
|
cell cycle |
4 |
|
cell transformation, neoplastic |
4 |
|
cell-free system |
4 |
|
cells, cultured |
4 |
|
chemotherapy-free |
4 |
|
chimera |
4 |
|
chinese patients |
4 |
|
chromosome banding |
4 |
|
chromosomes, human, pair 12 |
4 |
|
chromosomes, human, pair 14 |
4 |
|
chromosomes, human, pair 19 |
4 |
|
chromosomes, human, pair 20 |
4 |
|
chromosomes, human, pair 3 |
4 |
|
chromosomes, human, pair 7 |
4 |
|
chronic myeloid leukemia |
4 |
|
cisplatin |
4 |
|
clinical article |
4 |
|
clinical observations |
4 |
|
computer systems |
4 |
|
corpus callosum |
4 |
|
corticosteroid |
4 |
|
cyclin-dependent kinase inhibitor p16 - genetics - metabolism |
4 |
|
cyclophosphamide - administration & dosage |
4 |
|
cyclosporin |
4 |
|
cystitis - diagnosis - etiology - virology |
4 |
|
cystitis - etiology - pathology - urine - virology |
4 |
|
cytomegalovirus infections - blood - chemically induced - prevention & control |
4 |
|
cytomegalovirus reactivation |
4 |
|
daunorubicin - administration & dosage |
4 |
|
death-associated protein kinases - genetics - metabolism |
4 |
|
deep vein thrombosis |
4 |
|
dexamethasone |
4 |
|
diffusion-weighted imaging |
4 |
|
dna - blood - genetics |
4 |
|
dna - metabolism |
4 |
|
dna fingerprinting |
4 |
|
dna, neoplasm - genetics |
4 |
|
dna, viral - analysis - blood - urine |
4 |
|
drug reaction |
4 |
|
drug resistance |
4 |
|
dwi |
4 |
|
embryo, mammalian - physiology |
4 |
|
epigenesis, genetic - drug effects |
4 |
|
epstein-barr virus dna |
4 |
|
epstein-barr virus infections - complications - drug therapy - pathology |
4 |
|
event-free survival |
4 |
|
factor xii deficiency - complications - ethnology |
4 |
|
fdg-avid lymphoma |
4 |
|
flt3/internal tandem duplication |
4 |
|
fluorescent antibody technique, indirect |
4 |
|
gelatinase |
4 |
|
gene amplification |
4 |
|
gene expression |
4 |
|
genes, p53 |
4 |
|
genes, tumor suppressor |
4 |
|
genetic markers |
4 |
|
glucocorticoids - therapeutic use |
4 |
|
graft vs host disease - diagnosis - etiology - pathology |
4 |
|
graft vs host disease - epidemiology - etiology - microbiology |
4 |
|
granulocytes |
4 |
|
gut toxicity |
4 |
|
gvhd |
4 |
|
haemorrhagic cystitis |
4 |
|
haploinsufficiency |
4 |
|
hbv reactivation |
4 |
|
head and neck cancers |
4 |
|
head and neck carcinomas |
4 |
|
heart failure |
4 |
|
helicobacter infections - immunology |
4 |
|
hematoma, subdural - etiology |
4 |
|
hematopoiesis |
4 |
|
hematopoietic stem cells - cytology - physiology |
4 |
|
hematuria - diagnosis - etiology - virology |
4 |
|
hemorrhage - etiology - pathology - surgery - virology |
4 |
|
hepatitis - drug therapy - etiology - pathology |
4 |
|
hepatitis b - complications - drug therapy - virology |
4 |
|
hepatitis b - drug therapy - etiology - pathology |
4 |
|
hepatitis b - epidemiology |
4 |
|
hepatitis b - mortality - therapy - virology |
4 |
|
hepatitis b surface antigens - metabolism |
4 |
|
hepatitis b virus - genetics - immunology |
4 |
|
hepatitis b virus - growth & development |
4 |
|
hepatitis b virus - physiology |
4 |
|
hepatitis b, chronic - drug therapy - immunology |
4 |
|
hepatitis b, chronic - etiology - immunology - transmission |
4 |
|
herpes zoster |
4 |
|
herpes zoster - epidemiology - etiology - pathology |
4 |
|
herpesvirus 4, human - isolation & purification - physiology |
4 |
|
histocompatibility |
4 |
|
histocompatibility testing - methods |
4 |
|
hla antigens - analysis |
4 |
|
hla antigens - genetics |
4 |
|
hla typing |
4 |
|
hodgkin disease - drug therapy - pathology - virology |
4 |
|
homing |
4 |
|
ibrutinib |
4 |
|
immunocompetence |
4 |
|
immunocompromised host - drug effects |
4 |
|
immunoglobulin a - chemistry |
4 |
|
immunosuppressive agents - administration and dosage |
4 |
|
immunotherapy |
4 |
|
interventions |
4 |
|
ischemic cardiomyopathy |
4 |
|
janus kinase 2 - genetics |
4 |
|
lamivudine - therapeutic use |
4 |
|
leukemia stem cells |
4 |
|
leukemia, lymphocytic, chronic, b-cell - diagnosis - genetics |
4 |
|
leukemia, myeloid - complications - drug therapy |
4 |
|
leukemia, myeloid - complications - therapy |
4 |
|
leukemia, myeloid, acute - therapy |
4 |
|
leukemia, promyelocytic, acute - diagnosis - genetics |
4 |
|
leukemia, promyelocytic, acute - drug therapy - mortality |
4 |
|
leukemia, promyelocytic, acute - drug therapy - mortality - therapy |
4 |
|
leukemia, promyelocytic, acute - drug therapy - pathology |
4 |
|
leukemia, t-cell - genetics - immunology - mortality - pathology |
4 |
|
leukocytes, mononuclear |
4 |
|
life tables |
4 |
|
liver - pathology |
4 |
|
liver diseases - drug therapy - etiology - pathology |
4 |
|
liver diseases - etiology - pathology |
4 |
|
liver failure, acute - epidemiology - etiology |
4 |
|
liver transplantation - adverse effects |
4 |
|
liver transplantation - immunology |
4 |
|
longitudinal studies |
4 |
|
lymph node metastasis |
4 |
|
lymphocyte depletion |
4 |
|
lymphocytes - pathology |
4 |
|
lymphoma - blood - complications - drug therapy - virology |
4 |
|
lymphoma - diagnosis - pathology - therapy |
4 |
|
lymphoma, b-cell - metabolism - pathology - radionuclide imaging |
4 |
|
lymphoma, large b-cell, diffuse - drug therapy - pathology - virology |
4 |
|
lymphoma, non-hodgkin - diagnosis - drug therapy - radiotherapy |
4 |
|
lymphoma, non-hodgkin - genetics |
4 |
|
lymphoma, t-cell - drug therapy - pathology |
4 |
|
lymphoma, t-cell - genetics - immunology - mortality - pathology |
4 |
|
lymphoma, t-cell - genetics - pathology |
4 |
|
lymphoma, t-cell - immunology - pathology - radionuclide imaging |
4 |
|
lymphoma, t-cell - metabolism - pathology - radionuclide imaging |
4 |
|
lymphoma, t-cell, peripheral - diagnosis - drug therapy - radiotherapy |
4 |
|
marrow biopsy |
4 |
|
matrix metalloproteinase 2 - blood |
4 |
|
matrix metalloproteinase 9 - blood |
4 |
|
melanoma |
4 |
|
methylation |
4 |
|
micro-rna |
4 |
|
micrornas - genetics - metabolism |
4 |
|
mir-874-3p |
4 |
|
mixed chimerism |
4 |
|
molecular probes - genetics |
4 |
|
monitoring, physiologic - methods |
4 |
|
monomorphic epitheliotropic intestinal t cell lymphoma |
4 |
|
multiple myeloma |
4 |
|
multiple myeloma - genetics |
4 |
|
myelodysplasia |
4 |
|
myeloma |
4 |
|
myeloproliferative disease |
4 |
|
myeloproliferative neoplasms |
4 |
|
nasopharyngeal neoplasms - blood - mortality - pathology |
4 |
|
nasopharyngeal neoplasms - blood - pathology |
4 |
|
nasopharyngeal neoplasms - genetics |
4 |
|
natural killer cell lymphoma/leukaemia |
4 |
|
natural killer t-cells - immunology - pathology |
4 |
|
neoplasm recurrence, local |
4 |
|
neoplasm, residual - diagnosis |
4 |
|
neoplasms, multiple primary |
4 |
|
neoplasms, second primary |
4 |
|
neoplasms, second primary - chemically induced |
4 |
|
neutropenia |
4 |
|
nod/scid mice |
4 |
|
non-hodgkin lymphoma |
4 |
|
nonsmall cell lung cancer |
4 |
|
nose neoplasms - diagnosis - drug therapy - radiotherapy |
4 |
|
nose neoplasms - genetics - pathology |
4 |
|
nose neoplasms - immunology - pathology - radionuclide imaging |
4 |
|
occult hepatitis b |
4 |
|
oncogene proteins, fusion - analysis |
4 |
|
oncogene proteins, fusion - genetics |
4 |
|
oral |
4 |
|
osteopontin |
4 |
|
outcome |
4 |
|
oxides - administration & dosage - blood - therapeutic use |
4 |
|
pad |
4 |
|
pancytopenia - blood - complications - drug therapy - virology |
4 |
|
papillomavirus infections - diagnosis - etiology - virology |
4 |
|
papillomavirus infections - etiology - pathology |
4 |
|
pd1 |
4 |
|
pdl1 |
4 |
|
pdl2 |
4 |
|
plasma |
4 |
|
platelet count |
4 |
|
ploidies |
4 |
|
point mutation |
4 |
|
polyomavirus infections - blood - urine - virology |
4 |
|
polyomavirus infections - complications - diagnosis |
4 |
|
positron emission tomography computed tomography |
4 |
|
postoperative complications - blood - urine - virology |
4 |
|
precursor cell lymphoblastic leukemia-lymphoma - drug therapy - etiology |
4 |
|
precursor cell lymphoblastic leukemia-lymphoma - drug therapy - therapy |
4 |
|
prednisolone |
4 |
|
prednisone - administration & dosage |
4 |
|
primary myelofibrosis |
4 |
|
prognostic factor |
4 |
|
protein-serine-threonine kinases - genetics - metabolism |
4 |
|
proto-oncogene proteins |
4 |
|
purpura, thrombocytopenic - ethnology - immunology - physiopathology - therapy |
4 |
|
purpura, thrombocytopenic, idiopathic - drug therapy - genetics - immunology |
4 |
|
quantitative pcr |
4 |
|
receptors, antigen, t-cell, gamma-delta - genetics |
4 |
|
recurrence - prevention & control |
4 |
|
renal transplantation |
4 |
|
repressor proteins - genetics - metabolism |
4 |
|
reverse transcriptase inhibitors - therapeutic use |
4 |
|
risk |
4 |
|
rna, messenger - genetics |
4 |
|
rna, neoplasm - analysis |
4 |
|
rna, viral - analysis |
4 |
|
sepsis |
4 |
|
sequence deletion |
4 |
|
severe combined immunodeficiency |
4 |
|
severe combined immunodeficiency - pathology - therapy |
4 |
|
sheep - embryology |
4 |
|
sialoglycoproteins - blood |
4 |
|
signal transduction - genetics |
4 |
|
skin - pathology |
4 |
|
solid tumors |
4 |
|
standardized uptake value |
4 |
|
stem cell transplantation - adverse effects - methods |
4 |
|
stem cells - chemistry - physiology |
4 |
|
steroids - therapeutic use |
4 |
|
sulfites - pharmacology |
4 |
|
survival |
4 |
|
suv max |
4 |
|
t-cell |
4 |
|
t-cell receptor delta |
4 |
|
t-lymphocytes |
4 |
|
telomerase |
4 |
|
telomerase - genetics - metabolism |
4 |
|
therapeutic irrigation - methods |
4 |
|
therapeutic trials |
4 |
|
tp53 network |
4 |
|
transplantation |
4 |
|
transplantation chimera |
4 |
|
transplantation conditioning - adverse effects - methods |
4 |
|
trisomy |
4 |
|
tumor markers, biological |
4 |
|
tumor markers, biological - genetics |
4 |
|
tumor suppressor proteins - genetics |
4 |
|
tumor virus infections - blood - urine - virology |
4 |
|
tumor virus infections - etiology - pathology |
4 |
|
urinary bladder - metabolism - pathology |
4 |
|
urinary tract infections - diagnosis - urine - virology |
4 |
|
valganciclovir |
4 |
|
varicella-zoster virus |
4 |
|
vincristine - administration & dosage |
4 |
|
viremia - virology |
4 |
|
virus activation - drug effects |
4 |
|
whole-body irradiation |
4 |
|
whole-body mri |
4 |
|
x chromosome |
4 |
|
y chromosome |
4 |
|
y chromosome - genetics |
4 |
|
21) |
3 |
|
5-azacytidine |
3 |
|
6-mercaptopurine - administration & dosage |
3 |
|
abdominal pain - etiology |
3 |
|
actuarial analysis |
3 |
|
acute disseminated encephalomyelitis |
3 |
|
acute leukaemia |
3 |
|
acute leukemia |
3 |
|
acute myeloid leukaemia |
3 |
|
acute myeloid leukemia (aml) |
3 |
|
adaptor proteins, signal transducing - genetics - metabolism |
3 |
|
adenine nucleotides - administration & dosage - adverse effects |
3 |
|
adenoviruses, human - isolation & purification |
3 |
|
adult acute leukemias |
3 |
|
age-adjusted international index |
3 |
|
all |
3 |
|
allogeneic |
3 |
|
allogeneic bone-marrow transplantation (bmt) |
3 |
|
allogeneic haematopoietic stem cell transplantation |
3 |
|
amyloidosis - diagnosis - etiology - pathology - radionuclide imaging |
3 |
|
analgesics - adverse effects - therapeutic use |
3 |
|
anemia, aplastic - therapy |
3 |
|
anemia, hemolytic - diagnosis - etiology |
3 |
|
anemia, macrocytic - etiology |
3 |
|
anemia, megaloblastic - epidemiology - etiology - pathology |
3 |
|
anemia, pernicious - complications |
3 |
|
anemia, refractory - complications - diagnosis - pathology |
3 |
|
anemia, refractory - diagnosis - etiology - therapy |
3 |
|
anemia, sideroblastic - complications |
3 |
|
angiogenesis |
3 |
|
angiolymphoid hyperplasia with eosinophilia - etiology - genetics - pathology |
3 |
|
angiolymphoid hyperplasia with eosinophilia - genetics |
3 |
|
angiolymphoid hyperplasia with eosinophilia - genetics - pathology |
3 |
|
animal cell |
3 |
|
animal experiment |
3 |
|
animal model |
3 |
|
animal tissue |
3 |
|
anti-infective agents - therapeutic use |
3 |
|
antibiotics, antineoplastic - therapeutic use |
3 |
|
antibodies, neoplasm - administration & dosage |
3 |
|
anticonvulsants - adverse effects - therapeutic use |
3 |
|
antigens, cd - metabolism |
3 |
|
antigens, cd3 |
3 |
|
antigens, cd8 - metabolism |
3 |
|
antigens, differentiation, t-lymphocyte - metabolism |
3 |
|
antilymphocyte serum - therapeutic use |
3 |
|
antimetabolites, antineoplastic - administration & dosage - adverse effects |
3 |
|
antineoplastic agents - administration & dosage |
3 |
|
antineoplastic agents - adverse effects |
3 |
|
antineoplastic agents - pharmacology |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - adverse effects |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - therapeutic use |
3 |
|
antineoplastic combined chemotherapy protocols - pharmacology - therapeutic use |
3 |
|
antirheumatic agents - administration & dosage - adverse effects |
3 |
|
antisense |
3 |
|
apoptosis |
3 |
|
apoptosis regulatory proteins - genetics |
3 |
|
arabinonucleosides - administration & dosage - adverse effects |
3 |
|
arsenic |
3 |
|
arsenicals - administration & dosage - pharmacology |
3 |
|
arsenicals - adverse effects |
3 |
|
aryl hydrocarbon hydroxylases |
3 |
|
asparaginase - administration & dosage |
3 |
|
asparaginase - administration & dosage - adverse effects |
3 |
|
atg |
3 |
|
autoimmune diseases |
3 |
|
autoimmune diseases - complications - drug therapy - metabolism |
3 |
|
autoimmune thyroid disease |
3 |
|
autologous |
3 |
|
autologous bone marrow transplantation |
3 |
|
autologous stem cell transplantation |
3 |
|
autopsy |
3 |
|
azathioprine |
3 |
|
azathioprine - adverse effects |
3 |
|
b |
3 |
|
bcl-6 gene |
3 |
|
bcl10 |
3 |
|
beta-thalassemia - epidemiology |
3 |
|
biopsy, needle |
3 |
|
bk virus |
3 |
|
bk virus - genetics - isolation & purification - physiology |
3 |
|
bkv |
3 |
|
bleomycin - administration & dosage |
3 |
|
blood cells - chemistry |
3 |
|
blood transfusion, autologous |
3 |
|
blotting, western |
3 |
|
bmt recipients |
3 |
|
bone marrow cells - virology |
3 |
|
bone marrow transplantation - immunology - methods - mortality |
3 |
|
bone neoplasms - radiography - secondary |
3 |
|
boronic acids - pharmacology |
3 |
|
bortezomib-based induction |
3 |
|
brain neoplasms - immunology - pathology - secondary |
3 |
|
breast neoplasms - pathology |
3 |
|
bronchoalveolar lavage fluid - virology |
3 |
|
burkitt lymphoma - drug therapy - etiology - metabolism - virology |
3 |
|
burkitt lymphoma - drug therapy - genetics - pathology |
3 |
|
cadherins - genetics |
3 |
|
cadherins - genetics - metabolism |
3 |
|
cadherins-genetics |
3 |
|
calcinosis - etiology - radionuclide imaging |
3 |
|
candidiasis - chemically induced - pathology |
3 |
|
carcinoma - genetics - pathology |
3 |
|
carcinoma, hepatocellular - genetics - metabolism - physiopathology |
3 |
|
carmustine - administration & dosage |
3 |
|
carrier proteins |
3 |
|
carrier proteins - metabolism |
3 |
|
carrier state - virology |
3 |
|
castleman's disease |
3 |
|
catheters, indwelling - adverse effects |
3 |
|
cd3 antigen |
3 |
|
cd4 antigen |
3 |
|
cd56 antigen |
3 |
|
cd8 antigen |
3 |
|
cdkn2a |
3 |
|
cdkn2b |
3 |
|
cell aging |
3 |
|
cell cycle - drug effects |
3 |
|
cell nucleus - metabolism |
3 |
|
cell nucleus - ultrastructure |
3 |
|
cell proliferation - drug effects |
3 |
|
cell shape |
3 |
|
cell transformation, neoplastic - genetics |
3 |
|
cell transformation, neoplastic - genetics - pathology |
3 |
|
cell transformation, viral - drug effects |
3 |
|
central venous catheter |
3 |
|
ceop |
3 |
|
chemotherapy |
3 |
|
childhood |
3 |
|
china - ethnology |
3 |
|
chinese people |
3 |
|
chondrocytes - metabolism |
3 |
|
chorionic villi - ultrastructure - virology |
3 |
|
chromosome disorders |
3 |
|
chromosome mapping |
3 |
|
chromosomes, human, pair 1 |
3 |
|
chromosomes, human, pair 11 - genetics - ultrastructure |
3 |
|
chromosomes, human, pair 14 - genetics - ultrastructure |
3 |
|
chromosomes, human, pair 17 |
3 |
|
chromosomes, human, pair 22 - genetics |
3 |
|
chromosomes, human, pair 4 |
3 |
|
chromosomes, human, pair 9 |
3 |
|
chromosomes, human, pair 9 - genetics |
3 |
|
chromosomes, human, x |
3 |
|
chronic graft versus host disease |
3 |
|
chronic lymphoproliferative disorders |
3 |
|
chronic myeloid leukaemia (cml) |
3 |
|
ciprofloxacin - therapeutic use |
3 |
|
clara cell protein |
3 |
|
clonal evolution |
3 |
|
clonality |
3 |
|
cml |
3 |
|
cns disease |
3 |
|
collagen type x - genetics - immunology - physiology |
3 |
|
combined modality therapy |
3 |
|
communicable diseases |
3 |
|
complete remission |
3 |
|
computed tomography |
3 |
|
consensus |
3 |
|
copper - deficiency |
3 |
|
core binding factor alpha 2 subunit |
3 |
|
core-promoter |
3 |
|
coronary artery disease |
3 |
|
coronary artery disease - diagnosis - surgery |
3 |
|
cpg island |
3 |
|
cpg islands |
3 |
|
croup |
3 |
|
cyclin-dependent kinase inhibitor p15 - metabolism |
3 |
|
cyclin-dependent kinase inhibitor p16 - metabolism |
3 |
|
cyclin-dependent kinase inhibitor proteins - genetics |
3 |
|
cyclosporine |
3 |
|
cystitis - etiology - prevention & control - virology |
3 |
|
cystitis - etiology - urine |
3 |
|
cytarabine - administration & dosage - adverse effects |
3 |
|
cytarabine - administration and dosage - adverse effects |
3 |
|
cytochrome p-450 enzyme system - genetics |
3 |
|
cytology and histology |
3 |
|
cytomegalovirus - drug effects |
3 |
|
cytomegalovirus retinitis |
3 |
|
cytoplasmic granules - ultrastructure |
3 |
|
dacarbazine - administration & dosage |
3 |
|
de novo aml |
3 |
|
deauville score (ds) |
3 |
|
diagnostic errors |
3 |
|
diphenhydramine - therapeutic use |
3 |
|
dlbc |
3 |
|
dna - analysis |
3 |
|
dna chimerism |
3 |
|
dna fragmentation |
3 |
|
dna methylation - drug effects |
3 |
|
dna, neoplasm - analysis |
3 |
|
dna, neoplasm - metabolism |
3 |
|
dna, viral - genetics - isolation & purification |
3 |
|
dna-binding proteins |
3 |
|
dna-binding proteins - physiology |
3 |
|
down-regulation |
3 |
|
doxorubicin - administration & dosage |
3 |
|
droplet digital polymerase chain reaction |
3 |
|
drug screening assays, antitumor |
3 |
|
drug synergism |
3 |
|
drug toxicity |
3 |
|
e2f transcription factors |
3 |
|
e2f1 transcription factor |
3 |
|
ear canal - pathology |
3 |
|
ear neoplasms - drug therapy - pathology |
3 |
|
eber |
3 |
|
electrocardiography |
3 |
|
electrocardiography, ambulatory |
3 |
|
encephalomyelitis, acute disseminated - diagnosis - etiology - virology |
3 |
|
endothelium, vascular - injuries |
3 |
|
enteropathy-sssociated t-cell lymphoma - immunology - pathology - physiopathology - therapy |
3 |
|
epidemiologic studies |
3 |
|
epigenesis, genetic |
3 |
|
epigenetic modifiers |
3 |
|
epirubicin - administration & dosage |
3 |
|
epithelial cells - cytology - metabolism |
3 |
|
epithelial cells - drug effects - metabolism - pathology |
3 |
|
epstein-barr virus-expressed rna |
3 |
|
erythrocytes - chemistry |
3 |
|
erythrocytes, abnormal - ultrastructure |
3 |
|
esophageal cancer |
3 |
|
esophageal neoplasms - genetics |
3 |
|
esophageal neoplasms - genetics - pathology - virology |
3 |
|
esophagus - cytology - metabolism |
3 |
|
etoposide - administration & dosage |
3 |
|
etoposide - adverse effects - therapeutic use |
3 |
|
exanthema - chemically induced - microbiology |
3 |
|
exercise test - methods |
3 |
|
exons |
3 |
|
extracellular matrix - metabolism |
3 |
|
extranodal natural killer/t-cell lymphoma (enktl) |
3 |
|
eye infections, viral - diagnosis - immunology - therapy |
3 |
|
eyelid diseases - etiology |
3 |
|
failure-free survival |
3 |
|
feces - virology |
3 |
|
first completion remission |
3 |
|
flt-3 aberrations |
3 |
|
flt3 |
3 |
|
fusion proteins, bcr-abl |
3 |
|
gamma-aminobutyric acid - adverse effects - analogs & derivatives - therapeutic use |
3 |
|
ganciclovir - administration & dosage - analogs & derivatives |
3 |
|
gastric lymphoma |
3 |
|
gastritis-genetics |
3 |
|
gastrointestinal neoplasms - immunology - pathology - physiopathology - therapy |
3 |
|
gastrointestinal tract - chemistry - virology |
3 |
|
gene expression regulation |
3 |
|
gene expression regulation - genetics |
3 |
|
gene expression regulation, viral |
3 |
|
gene mutations |
3 |
|
gene rearrangement, beta-chain t-cell antigen receptor |
3 |
|
gene rearrangement, gamma-chain t-cell antigen receptor |
3 |
|
gene rearrangement, t-lymphocyte |
3 |
|
gene silencing |
3 |
|
gene therapy |
3 |
|
genes |
3 |
|
genes, p16 - genetics |
3 |
|
genes, p16 - physiology |
3 |
|
genes, t-cell receptor - genetics |
3 |
|
genes, viral |
3 |
|
gestational trophoblastic disease |
3 |
|
gestational trophoblastic disease - drug therapy - pathology |
3 |
|
glucosephosphate dehydrogenase - blood - genetics |
3 |
|
glucosephosphate dehydrogenase deficiency - genetics |
3 |
|
glycosaminoglycans - metabolism |
3 |
|
glycosylphosphatidyl-inositol-linked proteins |
3 |
|
glycosylphosphatidylinositols - blood |
3 |
|
graft vs host disease |
3 |
|
graft vs host disease - immunology |
3 |
|
graft vs host disease - virology |
3 |
|
graft vs tumor effect |
3 |
|
graft-versus-host disease (gvhd) |
3 |
|
granular lymphocytes |
3 |
|
granulocytic sarcoma |
3 |
|
granuloma, lethal midline - diagnosis |
3 |
|
granuloma, lethal midline - diagnosis - pathology - therapy |
3 |
|
guidelines |
3 |
|
haematopoietic sct |
3 |
|
haplotypes |
3 |
|
head and neck neoplasms - genetics |
3 |
|
heart conduction system - drug effects - physiopathology |
3 |
|
heart neoplasms - diagnosis - pathology |
3 |
|
heart rate - drug effects |
3 |
|
helicobacter infections - complications - genetics - metabolism |
3 |
|
helicobacter-infections-genetics |
3 |
|
helicobacter-pylori |
3 |
|
hematologic malignancy |
3 |
|
hematologic neoplasms - genetics |
3 |
|
hematologic neoplasms - mortality - therapy |
3 |
|
hematologic-neoplasms-drug-therapy |
3 |
|
hematological cancers |
3 |
|
hematopoietic stem cell transplantation - methods |
3 |
|
hematopoietic stem cell transplantation - utilization |
3 |
|
hematopoietic stem cells |
3 |
|
hematopoietic system |
3 |
|
hemoglobins - analysis |
3 |
|
hemoglobinuria, paroxysmal - blood |
3 |
|
hepatitis b - etiology - mortality |
3 |
|
hepatitis b - surgery |
3 |
|
hepatitis b surface antigens |
3 |
|
hepatitis b surface antigens - analysis |
3 |
|
hepatitis b virus - genetics |
3 |
|
hepatitis e - immunology |
3 |
|
hepatitis e virus - immunology |
3 |
|
hepatitis-b-prevention-and-control |
3 |
|
hepatitis-b-virus-physiology |
3 |
|
herpes zoster ophthalmicus - diagnosis - immunology - therapy |
3 |
|
herpesvirus 4, human - genetics - isolation & purification |
3 |
|
herpesvirus 4, human - isolation & purification |
3 |
|
herpesvirus 4, human - metabolism |
3 |
|
heterozygote detection |
3 |
|
histamine h1 antagonists - therapeutic use |
3 |
|
histocompatibility - immunology |
3 |
|
hla haplotype |
3 |
|
hla-a2 antigen |
3 |
|
hla-b antigens |
3 |
|
hla-dr antigens |
3 |
|
hla-dr serological subtypes |
3 |
|
hla-identical siblings |
3 |
|
hnscc |
3 |
|
hodgkin disease - drug therapy - mortality - pathology |
3 |
|
hodgkin's disease |
3 |
|
hpv |
3 |
|
hpv16 |
3 |
|
hydroxyurea - therapeutic use |
3 |
|
hyperplasia |
3 |
|
hyperthyroidism |
3 |
|
hypothyroidism |
3 |
|
idarubicin |
3 |
|
idarubicin - administration & dosage - pharmacology |
3 |
|
igh |
3 |
|
il2 |
3 |
|
immortalization |
3 |
|
immuno-reconstitution |
3 |
|
immunoglobulin heavy chain |
3 |
|
immunoglobulin lambda-chains - analysis |
3 |
|
immunophenotype |
3 |
|
in situ hybridization, fluorescence - methods |
3 |
|
independent of iss |
3 |
|
indolent |
3 |
|
inhibitor of differentiation protein 1 - chemistry - deficiency - metabolism |
3 |
|
inhibitory concentration 50 |
3 |
|
intensive chemotherapy |
3 |
|
interleukin-2 - pharmacology - physiology |
3 |
|
interleukin-6 |
3 |
|
internal tandem duplication of fms‐like tyrosine kinase 3 (flt3‐itd) |
3 |
|
interphase - genetics |
3 |
|
intestinal neoplasms - immunology - pathology |
3 |
|
intestinal obstruction - etiology |
3 |
|
intestinal perforation - etiology |
3 |
|
intracellular signaling peptides and proteins |
3 |
|
janus kinase 1 |
3 |
|
jejunal neoplasms - diagnosis - immunology - pathology |
3 |
|
kaplan-meier estimate |
3 |
|
karyotypic changes |
3 |
|
killer cells, natural - cytology - metabolism |
3 |
|
killer cells, natural - drug effects - pathology |
3 |
|
killer cells, natural - immunology |
3 |
|
killer cells, natural - radionuclide imaging |
3 |
|
kimura's disease |
3 |
|
kit |
3 |
|
lactate dehydrogenase |
3 |
|
lamivudine-therapeutic-use |
3 |
|
large granular lymphocytic leukemia |
3 |
|
leucovorin - administration & dosage |
3 |
|
leukemia - genetics |
3 |
|
leukemia, large granular lymphocytic - diagnosis - drug therapy - epidemiology |
3 |
|
leukemia, lymphocytic, chronic, b-cell - genetics |
3 |
|
leukemia, lymphoid - complications - drug therapy |
3 |
|
leukemia, lymphoid - ethnology - pathology - therapy |
3 |
|
leukemia, megakaryoblastic, acute - genetics |
3 |
|
leukemia, monocytic, acute - genetics |
3 |
|
leukemia, myelogenous, chronic, bcr-abl positive - blood - drug therapy - genetics - pathology |
3 |
|
leukemia, myelogenous, chronic, bcr-abl positive - genetics - therapy |
3 |
|
leukemia, myelogenous, chronic, bcr-abl positive - immunology - therapy |
3 |
|
leukemia, myelogenous, chronic, bcr-abl positive - pathology |
3 |
|
leukemia, myeloid - chemically induced - genetics - radionuclide imaging |
3 |
|
leukemia, myeloid - diagnosis - radiography |
3 |
|
leukemia, myeloid - drug therapy - mortality |
3 |
|
leukemia, myeloid - epidemiology - pathology |
3 |
|
leukemia, myeloid - etiology - genetics |
3 |
|
leukemia, myeloid - genetics - physiopathology - therapy |
3 |
|
leukemia, myeloid - metabolism |
3 |
|
leukemia, myeloid, acute - chemically induced |
3 |
|
leukemia, myeloid, acute - drug therapy |
3 |
|
leukemia, myeloid, acute - drug therapy - mortality |
3 |
|
leukemia, myeloid, acute - drug therapy - prevention & control |
3 |
|
leukemia, myeloid, acute - genetics - metabolism |
3 |
|
leukemia, myeloid, acute - genetics - mortality |
3 |
|
leukemia, myelomonocytic, acute - pathology |
3 |
|
leukemia, promyelocytic, acute - blood - drug therapy - genetics - pathology |
3 |
|
leukemia, promyelocytic, acute - chemically induced - drug therapy - etiology |
3 |
|
leukemia, promyelocytic, acute - complications - drug therapy |
3 |
|
leukemia, promyelocytic, acute - diagnosis - drug therapy |
3 |
|
leukemia, promyelocytic, acute - drug therapy - physiopathology |
3 |
|
leukemia, promyelocytic, acute - genetics - immunology - mortality |
3 |
|
leukemia, t-cell - drug therapy |
3 |
|
leukemia, t-cell - drug therapy - pathology |
3 |
|
leukocytes - chemistry |
3 |
|
literature review |
3 |
|
liver cirrhosis, alcoholic - complications |
3 |
|
liver neoplasms - diagnosis - drug therapy |
3 |
|
liver neoplasms - genetics - metabolism - physiopathology |
3 |
|
logistic models |
3 |
|
lung adenocarcinoma |
3 |
|
lung diseases - chemically induced - physiopathology |
3 |
|
lung function |
3 |
|
lupus nephritis - diagnosis |
3 |
|
lymph nodes - pathology - radionuclide imaging |
3 |
|
lymphatic diseases - etiology - pathology - radionuclide imaging |
3 |
|
lymphocyte transfusion |
3 |
|
lymphocytosis - genetics - immunology - microbiology |
3 |
|
lymphoma - classification - pathology - radiography |
3 |
|
lymphoma - diagnosis - pathology |
3 |
|
lymphoma - drug therapy - pathology |
3 |
|
lymphoma - drug therapy - radiotherapy - therapy |
3 |
|
lymphoma relapses post-hsct |
3 |
|
lymphoma, b-cell - complications - drug therapy |
3 |
|
lymphoma, b-cell - diagnosis - drug therapy |
3 |
|
lymphoma, b-cell - drug therapy - genetics - pathology |
3 |
|
lymphoma, b-cell - drug therapy - pathology |
3 |
|
lymphoma, b-cell - genetics |
3 |
|
lymphoma, b-cell, marginal zone - genetics |
3 |
|
lymphoma, extranodal nk-t-cell - complications - diagnosis |
3 |
|
lymphoma, extranodal nk-t-cell - metabolism |
3 |
|
lymphoma, large b-cell, diffuse - drug therapy - genetics - pathology |
3 |
|
lymphoma, large b-cell, diffuse - genetics |
3 |
|
lymphoma, large b-cell, diffuse - mortality |
3 |
|
lymphoma, large b-cell, diffuse - pathology - therapy |
3 |
|
lymphoma, mantle-cell - drug therapy - pathology |
3 |
|
lymphoma, non-hodgkin - drug therapy |
3 |
|
lymphoma, non-hodgkin - ethnology - genetics - mortality - pathology - therapy |
3 |
|
lymphoma, t-cell - complications - drug therapy |
3 |
|
lymphoma, t-cell - diagnosis |
3 |
|
lymphoma, t-cell - immunology - pathology |
3 |
|
lymphoma, t-cell - metabolism - pathology - virology |
3 |
|
lymphoma, t-cell - pathology - radionuclide imaging |
3 |
|
lymphoma, t-cell - therapy |
3 |
|
lymphoma, t-cell, peripheral - diagnosis - immunology - pathology |
3 |
|
lymphoproliferative diseases |
3 |
|
lymphoproliferative disorders - complications - drug therapy |
3 |
|
lymphoproliferative disorders - epidemiology - pathology |
3 |
|
lymphoproliferative disorders - therapy |
3 |
|
magnetic resonance angiography - methods |
3 |
|
marek disease - diagnosis - etiology - radionuclide imaging |
3 |
|
measurable-residual disease |
3 |
|
mechlorethamine - administration & dosage |
3 |
|
mediastinal neoplasms - genetics - pathology |
3 |
|
medical oncology - methods |
3 |
|
megaloblastic anaemia |
3 |
|
melphalan - administration & dosage |
3 |
|
melphalan - adverse effects - therapeutic use |
3 |
|
melphalan - therapeutic use |
3 |
|
membrane proteins - genetics |
3 |
|
meningeal neoplasms - chemically induced - genetics - radionuclide imaging |
3 |
|
meningeal neoplasms - drug therapy |
3 |
|
methotrexate - administration & dosage |
3 |
|
methylation-specific polymerase chain reaction |
3 |
|
methylprednisolone - therapeutic use |
3 |
|
minimal residual disease |
3 |
|
minimal residual disease (mro) |
3 |
|
mir129 |
3 |
|
mitoxantrone - administration and dosage - adverse effects |
3 |
|
models, biological |
3 |
|
monoclonal antibodies |
3 |
|
mucous membrane - pathology |
3 |
|
multiple myeloma - diagnosis - drug therapy - genetics |
3 |
|
multiple myeloma - diagnosis - mortality - therapy |
3 |
|
multiple myeloma - diagnosis - pathology - physiopathology - therapy |
3 |
|
multiple myeloma - drug therapy - pathology |
3 |
|
multiple myeloma - genetics - pathology |
3 |
|
multiple myeloma - genetics - pathology - therapy |
3 |
|
multiple myeloma - physiopathology |
3 |
|
muscular diseases - chemically induced - microbiology |
3 |
|
mutagenesis - drug effects |
3 |
|
mutants |
3 |
|
mycobacterium tuberculosis - pathogenicity |
3 |
|
myeloablative agents |
3 |
|
myeloablative agonists - adverse effects |
3 |
|
myelodysplastic syndrome |
3 |
|
myelodysplastic syndromes - chemically induced |
3 |
|
myeloid |
3 |
|
nasal cavity |
3 |
|
nasal nk/t lymphoma |
3 |
|
nasopharyngeal neoplasms - pathology |
3 |
|
nasopharyngeal neoplasms - surgery |
3 |
|
nasopharynx - cytology - metabolism |
3 |
|
natural killer cell |
3 |
|
natural killer-like t-cell lymphoma |
3 |
|
naturalkiller cell lymphoma |
3 |
|
neoplasm proteins - blood |
3 |
|
neoplasm, residual - genetics |
3 |
|
neoplasms, multiple primary - diagnosis - drug therapy |
3 |
|
neoplasms, second primary - chemically induced - genetics - radionuclide imaging |
3 |
|
neoplasms, second primary - drug therapy - etiology |
3 |
|
nerve degeneration - etiology |
3 |
|
neutropenia - drug therapy |
3 |
|
neutropenia - epidemiology |
3 |
|
neutrophils |
3 |
|
nf-kappa b - genetics - metabolism |
3 |
|
nf-κ |
3 |
|
nocodazole - pharmacology |
3 |
|
nose neoplasms |
3 |
|
nose neoplasms - diagnosis |
3 |
|
nose neoplasms - diagnosis - pathology - therapy |
3 |
|
nose neoplasms - drug therapy - radiotherapy - therapy |
3 |
|
nose neoplasms - therapy |
3 |
|
npm1 |
3 |
|
nuclear family |
3 |
|
nucleus |
3 |
|
occupational exposure |
3 |
|
oligoclonal reconstitution |
3 |
|
oligodeoxyribonucleotides |
3 |
|
omacetaxine mepesuccinate |
3 |
|
oncogene proteins - genetics |
3 |
|
oncogene proteins, fusion - blood |
3 |
|
oncogene proteins, viral - antagonists & inhibitors - biosynthesis - genetics |
3 |
|
oncogene proteins, viral - genetics - metabolism |
3 |
|
oncology medical sciences |
3 |
|
opportunistic infections |
3 |
|
opportunistic infections - diagnosis - immunology - therapy |
3 |
|
opportunistic infections - etiology - virology |
3 |
|
oral arsenic trioxide maintenance |
3 |
|
organ specificity |
3 |
|
osteolysis - pathology |
3 |
|
outcome assessment (health care) |
3 |
|
oxides - administration & dosage - pharmacology |
3 |
|
oxides - adverse effects |
3 |
|
pancytopenia - etiology |
3 |
|
papillomaviridae - isolation & purification |
3 |
|
para-influenza virus |
3 |
|
parainfluenza virus |
3 |
|
parainfluenza virus 3, human |
3 |
|
paramyxoviridae infections - chemically induced - complications |
3 |
|
paraneoplastic polyneuropathy - etiology |
3 |
|
paraneoplastic syndromes - etiology - pathology |
3 |
|
paraproteinemias - complications - diagnosis |
3 |
|
paraproteinemias - genetics |
3 |
|
paraproteins - analysis |
3 |
|
paresthesia - etiology |
3 |
|
paroxysmal nocturnal hemoglobinuria |
3 |
|
pathological diagnosis |
3 |
|
pemphigus - etiology - pathology |
3 |
|
pericardium - pathology |
3 |
|
peripheral t-cell lymphoma |
3 |
|
ph-negative leukaemia |
3 |
|
pilot projects |
3 |
|
piperazines - therapeutic use |
3 |
|
placenta - cytology - virology |
3 |
|
plasmids |
3 |
|
polycythemia vera - ethnology - physiopathology |
3 |
|
polyomavirus infections - drug therapy - etiology |
3 |
|
polyomavirus infections - drug therapy - virology |
3 |
|
polyomavirus infections - etiology |
3 |
|
polyomavirus infections - immunology - urine - virology |
3 |
|
poor engraftment |
3 |
|
positron emission tomography |
3 |
|
positron-emission tomography - methods - utilization - veterinary |
3 |
|
positron-emission tomography and computed tomography |
3 |
|
postoperative complications |
3 |
|
pre-core |
3 |
|
precursor b-cell lymphoblastic leukemia-lymphoma - genetics |
3 |
|
precursor cell lymphoblastic leukemia-lymphoma - drug therapy |
3 |
|
precursor cell lymphoblastic leukemia-lymphoma - drug therapy - mortality |
3 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics - mortality |
3 |
|
precursor cell lymphoblastic leukemia-lymphoma - therapy |
3 |
|
predictive value of tests |
3 |
|
premedication |
3 |
|
primary cardiac lymphoma |
3 |
|
primary gastrointestinal lymphoma |
3 |
|
primary mediastinal lymphoma |
3 |
|
primary myelofibrosis - epidemiology |
3 |
|
primary myelofibrosis - genetics |
3 |
|
procarbazine - administration & dosage |
3 |
|
profiling |
3 |
|
prognostication |
3 |
|
programmed cell death protein 1 |
3 |
|
promoter regions (genetics) - genetics |
3 |
|
promoter-regions-genetics-genetics |
3 |
|
protease inhibitors - therapeutic use |
3 |
|
protein kinase inhibitors - therapeutic use |
3 |
|
protein tyrosine phosphatase, non-receptor type 6 |
3 |
|
protein tyrosine phosphatases - metabolism |
3 |
|
protein-tyrosine kinases |
3 |
|
protein-tyrosine kinases - antagonists & inhibitors |
3 |
|
protein-tyrosine kinases - metabolism |
3 |
|
proteinuria - drug therapy - etiology |
3 |
|
proteoglycans - metabolism |
3 |
|
proto-oncogene proteins - metabolism |
3 |
|
proto-oncogene proteins c-akt - metabolism |
3 |
|
proto-oncogene proteins c-bcl-2 - biosynthesis - metabolism |
3 |
|
proto-oncogene proteins c-bcr |
3 |
|
pyrazines - pharmacology |
3 |
|
pyrazines - therapeutic use |
3 |
|
pyrimidines - therapeutic use |
3 |
|
quantification |
3 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
3 |
|
reactivation |
3 |
|
receptors, androgen - genetics |
3 |
|
receptors, antigen, t-cell - metabolism |
3 |
|
receptors, antigen, t-cell, gamma-delta - metabolism |
3 |
|
red-cell aplasia, pure - physiopathology - therapy |
3 |
|
regeneration |
3 |
|
relapsed |
3 |
|
relapsed apl |
3 |
|
repressor proteins - metabolism |
3 |
|
respiratory system - virology |
3 |
|
respiratory tract infections - chemically induced - complications |
3 |
|
respirovirus infections - etiology |
3 |
|
response assessment |
3 |
|
retinal necrosis syndrome, acute - diagnosis - immunology - therapy |
3 |
|
retinoblastoma protein - biosynthesis - metabolism |
3 |
|
retinoblastoma-binding protein 1 |
3 |
|
retreatment |
3 |
|
retroviridae - genetics |
3 |
|
retrovirus-mediated gene delivery |
3 |
|
rheumatoid arthritis |
3 |
|
ribosomal proteins - analysis |
3 |
|
risk assessment |
3 |
|
rna, antisense - administration & dosage - genetics |
3 |
|
rna, messenger - genetics - metabolism |
3 |
|
rna, viral |
3 |
|
rna-binding proteins - analysis |
3 |
|
second complete remission |
3 |
|
secondary aml |
3 |
|
secondary apl |
3 |
|
severe aplastic anemia |
3 |
|
sex characteristics |
3 |
|
siblings |
3 |
|
signal transduction |
3 |
|
sjogren's syndrome - diagnosis - etiology - pathology |
3 |
|
solvents |
3 |
|
splenomegaly - complications |
3 |
|
stat1 transcription factor |
3 |
|
steroid 16-alpha-hydroxylase |
3 |
|
steroid hydroxylases - genetics |
3 |
|
stomach neoplasms - genetics - metabolism - microbiology |
3 |
|
suppressor of cytokine signaling proteins |
3 |
|
sural nerve - pathology |
3 |
|
t(8 |
3 |
|
t-cell large granular lymphocyte leukaemia |
3 |
|
t-cell large granular lymphocyte leukemia |
3 |
|
t-lymphocytes - immunology - pathology |
3 |
|
t/nk cell lymphoma |
3 |
|
tandem repeat sequences |
3 |
|
target therapy |
3 |
|
targeted treatment |
3 |
|
tcr and igh genes rearrangement |
3 |
|
tdt |
3 |
|
telomerase - genetics |
3 |
|
telomere - genetics |
3 |
|
teniposide - administration & dosage |
3 |
|
therapy-related lymphoma |
3 |
|
thrombocythemia, essential - complications - drug therapy - mortality |
3 |
|
thrombocythemia, essential - complications - genetics - mortality - physiopathology |
3 |
|
thrombocytopenia - complications - therapy |
3 |
|
thrombocytopenia - epidemiology |
3 |
|
thrombocytosis - blood - genetics - physiopathology |
3 |
|
thrombocytosis - complications - drug therapy |
3 |
|
thrombosis |
3 |
|
thrombosis - complications |
3 |
|
thrombosis - epidemiology |
3 |
|
thrombosis - etiology - genetics |
3 |
|
thrombosis-free survival |
3 |
|
thymectomy |
3 |
|
thymic neoplasm |
3 |
|
thymidylate synthase |
3 |
|
thyroiditis, autoimmune - etiology |
3 |
|
thyroiditis, autoimmune - immunology |
3 |
|
tissue donors - statistics & numerical data |
3 |
|
tomography, emission-computed |
3 |
|
tomography, emission-computed, single-photon - methods |
3 |
|
trans-activators - physiology |
3 |
|
transcription factor dp1 |
3 |
|
transcription factors - biosynthesis - metabolism |
3 |
|
transcription factors - metabolism |
3 |
|
transformation |
3 |
|
translocation |
3 |
|
translocation, genetic - genetics |
3 |
|
transplant related mortality |
3 |
|
transplant-eligible myeloma |
3 |
|
transplantation chimera - genetics |
3 |
|
transplantation, autologous - utilization |
3 |
|
tretinoin - administration & dosage |
3 |
|
trismus - chemically induced |
3 |
|
tuberculosis |
3 |
|
tuberculosis - epidemiology - microbiology - mortality |
3 |
|
tumor suppressor protein p53 - genetics - metabolism |
3 |
|
tumor virus infections - drug therapy - etiology |
3 |
|
tumor virus infections - drug therapy - virology |
3 |
|
tumor virus infections - genetics - immunology - microbiology |
3 |
|
tumor virus infections - immunology - urine - virology |
3 |
|
tumour suppressor gene |
3 |
|
tumour suppressor genes |
3 |
|
urinary retention - etiology |
3 |
|
uterine cervical neoplasms - pathology - therapy |
3 |
|
uterine cervical neoplasms - pathology - therapy - virology |
3 |
|
uterine neoplasms - metabolism - secondary - virology |
3 |
|
uterus |
3 |
|
vad |
3 |
|
venous thrombosis |
3 |
|
venous thrombosis - etiology |
3 |
|
vinblastine - administration & dosage |
3 |
|
viral core proteins - genetics |
3 |
|
virus latency |
3 |
|
virus shedding |
3 |
|
virus-activation-drug-effects |
3 |
|
vitamin b 12 deficiency - complications |
3 |
|
vitamin b12 deficiency |
3 |
|
vocal cords - pathology |
3 |
|
voice disorders - diagnosis - etiology - virology |
3 |
|
warfarin - adverse effects |
3 |
|
xenograft |
3 |
|
+8 |
2 |
|
3-weekly daratumumab regimen |
2 |
|
67gallium |
2 |
|
aberrant methylation |
2 |
|
absorptiometry, photon |
2 |
|
acromegaly |
2 |
|
acromegaly - complications - surgery |
2 |
|
acute leukaemias |
2 |
|
acute leukemias |
2 |
|
acute myeloblastic leukemia |
2 |
|
acute promyelocitic leukaemia |
2 |
|
acute promyelocytic |
2 |
|
acute promyelocytic leukemia (apl) |
2 |
|
adenocarcinoma - chemically induced |
2 |
|
adenocarcinoma - etiology - pathology |
2 |
|
adenocarcinoma - genetics |
2 |
|
adenoma - complications - secretion - surgery |
2 |
|
adenoma - pathology |
2 |
|
advanced stage |
2 |
|
affordability |
2 |
|
aggressive myeloma |
2 |
|
aging - metabolism |
2 |
|
algorithms |
2 |
|
allogeneic hematopoietic cell transplantation |
2 |
|
allogeneic hematopoietic stem cell transplantation |
2 |
|
aml1, eto |
2 |
|
amyloidosis - diagnosis - immunology |
2 |
|
anaplastic lymphoma kinase |
2 |
|
anemia, hemolytic - etiology |
2 |
|
anemia, hemolytic, autoimmune - complications - drug therapy - surgery - therapy |
2 |
|
anemia, hemolytic, autoimmune - etiology |
2 |
|
anemia, refractory, with excess of blasts - genetics |
2 |
|
angina pectoris - complications - therapy |
2 |
|
ankylosing spondylitis |
2 |
|
anthrax - diagnosis |
2 |
|
anti-hbs |
2 |
|
anti-thymocyte globulin |
2 |
|
antibodies, monoclonal |
2 |
|
antibodies, monoclonal - adverse effects - therapeutic use |
2 |
|
antibodies, neoplasm - adverse effects - therapeutic use |
2 |
|
antifungal prophylaxis |
2 |
|
antigens, cd - analysis |
2 |
|
antigens, cd - immunology |
2 |
|
antigens, cd2 - analysis |
2 |
|
antigens, cd3 - analysis |
2 |
|
antigens, neoplasm - immunology |
2 |
|
antilymphocyte serum - administration & dosage |
2 |
|
antineoplastic agents - administration & dosage - adverse effects - therapeutic use |
2 |
|
antineoplastic agents - administration & dosage - blood - therapeutic use |
2 |
|
antineoplastic agents - administration and dosage |
2 |
|
antineoplastic agents - adverse effects - therapeutic use |
2 |
|
antineoplastic combined chemotherapy protocols |
2 |
|
antithrombin iii deficiency |
2 |
|
apl |
2 |
|
aplastic anaemia |
2 |
|
apoptosis - genetics |
2 |
|
aquaglyceroporin 9 |
2 |
|
aquaporins - drug effects - genetics - metabolism |
2 |
|
area under curve |
2 |
|
arginine - chemistry |
2 |
|
arginine - genetics |
2 |
|
arsenicals - administration & dosage - adverse effects - therapeutic use |
2 |
|
arsenicals - adverse effects - therapeutic use |
2 |
|
arsenicals - metabolism - pharmacokinetics - pharmacology |
2 |
|
arthritis, rheumatoid - complications - drug therapy |
2 |
|
arthritis, rheumatoid - drug therapy |
2 |
|
ascites - genetics - pathology |
2 |
|
asia-pacific |
2 |
|
asparaginase - administration and dosage |
2 |
|
atrial fibrillation |
2 |
|
autologous hematopoietic stem cell transplantation |
2 |
|
autologous regeneration |
2 |
|
azacitidine - pharmacology |
2 |
|
azacytidine |
2 |
|
azathioprine - therapeutic use |
2 |
|
b-lymphocytes - physiology |
2 |
|
back pain - etiology |
2 |
|
bacteremia - complications |
2 |
|
bcl-2 inhibitors |
2 |
|
benzamide |
2 |
|
biochemistry |
2 |
|
biological availability |
2 |
|
biological transport |
2 |
|
biology |
2 |
|
biomarkers |
2 |
|
bk virus - genetics |
2 |
|
blast crisis |
2 |
|
blast crisis - complications - diagnosis |
2 |
|
blast crisis - genetics |
2 |
|
blindness - chemically induced - therapy |
2 |
|
body weight loss |
2 |
|
bone density |
2 |
|
bone marrow - chemistry - physiology |
2 |
|
bone marrow cells - cytology - pathology |
2 |
|
bone marrow examination |
2 |
|
bone marrow neoplasms - genetics |
2 |
|
bone marrow neoplasms - immunology - pathology |
2 |
|
bone marrow neoplasms - metabolism - pathology - secondary |
2 |
|
bone neoplasms - diagnosis - secondary |
2 |
|
brachial artery - physiology |
2 |
|
brain diseases - etiology - radiography |
2 |
|
brain edema - etiology |
2 |
|
btk inhibitors |
2 |
|
burden |
2 |
|
c-reactive protein - analysis |
2 |
|
cadherins - metabolism |
2 |
|
calcium-binding proteins - genetics - metabolism |
2 |
|
calcium-calmodulin-dependent protein kinases - genetics |
2 |
|
carcinoma - etiology - genetics |
2 |
|
carcinoma, non-small-cell lung - genetics |
2 |
|
carotid body tumor - complications - pathology |
2 |
|
carrier proteins - genetics - metabolism |
2 |
|
carrier state |
2 |
|
catheter ablation |
2 |
|
catheterization, central venous - adverse effects |
2 |
|
cause of death |
2 |
|
ccaat-enhancer-binding protein-alpha - genetics |
2 |
|
cebpa |
2 |
|
cell culture techniques - methods |
2 |
|
cell cycle - genetics |
2 |
|
cell cycle proteins - genetics |
2 |
|
cell differentiation - genetics |
2 |
|
cell division - genetics |
2 |
|
cell line, transformed |
2 |
|
cell nucleolus - ultrastructure |
2 |
|
cell transformation, viral - genetics |
2 |
|
central nervous system - pathology |
2 |
|
cerebellar diseases - chemically induced |
2 |
|
chemotaxis, leukocyte |
2 |
|
chidamide |
2 |
|
chinese cll |
2 |
|
chromosome 17 |
2 |
|
chromosome 5 |
2 |
|
chromosome aberrations - genetics |
2 |
|
chromosome inversion |
2 |
|
chromosomes, human, pair 13 - genetics |
2 |
|
chromosomes, human, pair 2 |
2 |
|
chromosomes, human, pair 20 - genetics |
2 |
|
chromosomes, human, pair 21 - genetics |
2 |
|
chromosomes, human, pair 8 - genetics |
2 |
|
chronic eosinophilic leukemia |
2 |
|
chronic lymphocytic leukaemia |
2 |
|
chronic myelogenous leukemia |
2 |
|
ciclosporin |
2 |
|
cip/kip |
2 |
|
cki |
2 |
|
classical hodgkin lymphoma |
2 |
|
clinical applications |
2 |
|
clonal |
2 |
|
cloning, molecular |
2 |
|
coagulation |
2 |
|
codon - genetics |
2 |
|
collaboration |
2 |
|
colonic carcinoma |
2 |
|
colonic neoplasms - chemically induced |
2 |
|
comparative genomic hybridization |
2 |
|
confidence intervals |
2 |
|
coronary artery disease - complications - therapy |
2 |
|
coronary artery disease - pathology - physiopathology - surgery |
2 |
|
coronary circulation |
2 |
|
coronary disease - radionuclide imaging - surgery |
2 |
|
cost-effective |
2 |
|
cost-saving |
2 |
|
cyclin-dependent kinase inhibitor p15 - genetics |
2 |
|
cyclin-dependent kinase inhibitor p16 - genetics |
2 |
|
cyclin-dependent kinase inhibitor proteins - genetics - metabolism |
2 |
|
cyclin-dependent kinases - genetics |
2 |
|
cyclosporine - administration & dosage |
2 |
|
cystitis - virology |
2 |
|
cytarabine - administration & dosage - adverse effects - pharmacokinetics |
2 |
|
cytokines |
2 |
|
cytomegalovirus - drug effects - physiology |
2 |
|
cytomegalovirus infections - complications - drug therapy |
2 |
|
cytoplasm - ultrastructure |
2 |
|
dara-imid-dex regimen |
2 |
|
demethylating agents |
2 |
|
dexamethasone, therapeutic use |
2 |
|
diabetes |
2 |
|
diabetes mellitus, type 2 - complications - physiopathology |
2 |
|
diabetic angiopathies - prevention & control |
2 |
|
diagnostic imaging - standards |
2 |
|
diploidy |
2 |
|
disease susceptibility - epidemiology |
2 |
|
dna - genetics |
2 |
|
dna nucleotidylexotransferase |
2 |
|
dna ploidy |
2 |
|
dna repair - genetics |
2 |
|
dna, viral |
2 |
|
dna, viral - chemistry |
2 |
|
dna-binding proteins - metabolism |
2 |
|
donor follow-up |
2 |
|
donor lymphocyte infusion |
2 |
|
down syndrome - blood - complications - genetics |
2 |
|
drug resistance, neoplasm |
2 |
|
early death |
2 |
|
ebv |
2 |
|
efficacy |
2 |
|
eltrombopag |
2 |
|
endocardium |
2 |
|
endothelial cells - physiology |
2 |
|
endothelial function |
2 |
|
endothelial progenitor cells |
2 |
|
endothelium, vascular - physiology |
2 |
|
eosinophilic chloroma |
2 |
|
eosinophils |
2 |
|
eosinophils - pathology |
2 |
|
eosinophils - physiology |
2 |
|
epidemiology |
2 |
|
epithelial cells - cytology - physiology |
2 |
|
epstein-barr virus infections - etiology - pathology |
2 |
|
epstein-barr virus infections - immunology - virology |
2 |
|
equipment failure |
2 |
|
erythropoiesis |
2 |
|
escherichia coli infections - etiology |
2 |
|
europe - epidemiology |
2 |
|
extra-medullary disease |
2 |
|
extramedullary disease |
2 |
|
extramedullary relapse |
2 |
|
extranodal |
2 |
|
extranodal lymphoma |
2 |
|
extranodal nk/t-cell lymphoma |
2 |
|
fab classification |
2 |
|
factor v - genetics |
2 |
|
factor v - genetics - metabolism |
2 |
|
factor v deficiency - complications - ethnology - genetics |
2 |
|
far east |
2 |
|
feasibility studies |
2 |
|
flow cytometry - methods |
2 |
|
fluconazole |
2 |
|
fludarabine, therapeutic use |
2 |
|
fms-like tyrosine kinase 3 |
2 |
|
focal segmental glomerulosclerosis (fsgs) |
2 |
|
fruit |
2 |
|
fusion proteins, bcr-abl - analysis |
2 |
|
gallium radioisotopes - diagnostic use - pharmacokinetics |
2 |
|
ganciclovir - analogs & derivatives - therapeutic use |
2 |
|
gastric mucosa - physiology |
2 |
|
gastrointestinal neoplasms |
2 |
|
gastrointestinal neoplasms - mortality - pathology - therapy |
2 |
|
gene duplication |
2 |
|
gene rearrangement - genetics |
2 |
|
gene rearrangement, beta-chain t-cell antigen receptor - genetics |
2 |
|
genes, abl |
2 |
|
genes, immunoglobulin - genetics |
2 |
|
genes, mdr - genetics |
2 |
|
giant lymph node hyperplasia - radionuclide imaging |
2 |
|
glomerular mesangium - pathology |
2 |
|
glomerulonephritis-complications |
2 |
|
glomerulosclerosis, focal segmental - pathology |
2 |
|
glucose 6-phosphate dehydrogenase (g6pd) deficiency |
2 |
|
glucosephosphate dehydrogenase - genetics |
2 |
|
glucosephosphate dehydrogenase deficiency - epidemiology - genetics |
2 |
|
glucuronosyltransferase - genetics |
2 |
|
glycoproteins - immunology |
2 |
|
graft vs host disease - complications - pathology |
2 |
|
graft vs host disease - ethnology |
2 |
|
graft vs host disease - etiology |
2 |
|
graft vs host disease - mortality |
2 |
|
graft vs host disease - prevention and control |
2 |
|
graft-versus- leukemia effect |
2 |
|
graft-versus-host disease |
2 |
|
granulocyte colony-stimulating factor - genetics |
2 |
|
granuloma, lethal midline - pathology - therapy |
2 |
|
growth hormone - secretion |
2 |
|
growth inhibitors - adverse effects - therapeutic use |
2 |
|
gynecomastia |
2 |
|
gynecomastia - etiology - pathology |
2 |
|
hairy cell leukemia |
2 |
|
head and neck neoplasms - genetics - pathology |
2 |
|
health |
2 |
|
heart catheterization - methods |
2 |
|
heart neoplasms - drug therapy - secondary |
2 |
|
helicobacter infections - microbiology |
2 |
|
helicobacter pylori - metabolism |
2 |
|
hemangiosarcoma - genetics |
2 |
|
hematologic diseases - ethnology - therapy |
2 |
|
hematopoiesis - genetics |
2 |
|
hematopoiesis, extramedullary |
2 |
|
hematopoietic stem cell mobilization - methods - standards |
2 |
|
hemorrhage |
2 |
|
hepatitis b - immunology - transmission |
2 |
|
hepatitis b virus - classification - genetics - immunology |
2 |
|
hepatitis b, chronic - complications - therapy |
2 |
|
herpesviridae infections - pathology |
2 |
|
herpesvirus 4, human |
2 |
|
herpesvirus 4, human - genetics - metabolism |
2 |
|
heterosexuality |
2 |
|
histone deacetylase inhibitors |
2 |
|
history |
2 |
|
hla b27 |
2 |
|
hla-b27 antigen |
2 |
|
hla-indentical siblings |
2 |
|
hong kong - ethnology |
2 |
|
hsr |
2 |
|
human |
2 |
|
hyperbilirubinemia - chemically induced - genetics - metabolism |
2 |
|
hypereosinophilic syndrome - genetics |
2 |
|
hypereosinophilic syndrome - genetics - metabolism - radiography |
2 |
|
hypertension, malignant - complications |
2 |
|
ighv |
2 |
|
immortalized ovarian cell lines |
2 |
|
immunity |
2 |
|
immunoglobulin m - immunology |
2 |
|
immunosuppression - adverse effects - methods |
2 |
|
immunosuppressive agents - adverse effects |
2 |
|
indium radioisotopes - diagnostic use |
2 |
|
induction |
2 |
|
infant, newborn |
2 |
|
infusions, intravenous |
2 |
|
ink4 |
2 |
|
interphase |
2 |
|
interstitial 9q- |
2 |
|
intracellular signaling peptides and proteins - genetics |
2 |
|
intravascular lymphomatosis |
2 |
|
italian cll |
2 |
|
itraconazole |
2 |
|
jak/stat |
2 |
|
k562 cells |
2 |
|
kidney - physiopathology |
2 |
|
kidney failure, chronic - complications - physiopathology |
2 |
|
kidney failure, chronic - immunology - surgery - virology |
2 |
|
kidney glomerulus - pathology |
2 |
|
killer cells, natural - metabolism - pathology - radiography |
2 |
|
large cell transformation |
2 |
|
laser therapy - methods |
2 |
|
lectins, c-type |
2 |
|
leg |
2 |
|
leukemia - complications |
2 |
|
leukemia - etiology |
2 |
|
leukemia - etiology - metabolism |
2 |
|
leukemia, hairy cell - complications - diagnosis - drug therapy |
2 |
|
leukemia, hairy cell - epidemiology - pathology |
2 |
|
leukemia, lymphoid - pathology - therapy |
2 |
|
leukemia, myelocytic, acute - chemically induced |
2 |
|
leukemia, myelogenous, chronic, bcr-abl positive - complications |
2 |
|
leukemia, myelogenous, chronic, bcr-abl positive - complications - genetics |
2 |
|
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy - genetics |
2 |
|
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy - genetics - metabolism |
2 |
|
leukemia, myelogenous, chronic, bcr-abl positive - genetics - immunology - pathology |
2 |
|
leukemia, myelogenous, chronic, bcr-abl positive - genetics - pathology |
2 |
|
leukemia, myelogenous, chronic, bcr-abl positive - pathology - therapy |
2 |
|
leukemia, myeloid - blood - drug therapy |
2 |
|
leukemia, myeloid - chemically induced - complications - genetics |
2 |
|
leukemia, myeloid - diagnosis - genetics |
2 |
|
leukemia, myeloid - genetics - metabolism - therapy |
2 |
|
leukemia, myeloid - genetics - pathology |
2 |
|
leukemia, myeloid, acute - chemically induced - genetics |
2 |
|
leukemia, myeloid, acute - complications - pathology - therapy |
2 |
|
leukemia, myeloid, acute - genetics - immunology - pathology |
2 |
|
leukemia, myeloid, acute - genetics - therapy |
2 |
|
leukemia, myeloid, chronic, atypical, bcr-abl negative - genetics |
2 |
|
leukemia, myeloid, chronic-phase - genetics - pathology |
2 |
|
leukemia, myelomonocytic, acute - genetics |
2 |
|
leukemia, myelomonocytic, acute - genetics - immunology - pathology |
2 |
|
leukemia, myelomonocytic, chronic - genetics |
2 |
|
leukemia, promyelocytic, acute - blood - diagnosis - drug therapy |
2 |
|
leukemia, promyelocytic, acute - cerebrospinal fluid - pathology - radiography |
2 |
|
leukemia, promyelocytic, acute - diagnosis - drug therapy - genetics |
2 |
|
leukemia, promyelocytic, acute - diagnosis - drug therapy - physiopathology |
2 |
|
leukemia, promyelocytic, acute - drug therapy - genetics - pathology |
2 |
|
leukemia, promyelocytic, acute - drug therapy - metabolism |
2 |
|
leukemia, promyelocytic, acute - etiology - genetics |
2 |
|
leukemia, promyelocytic, acute - genetics - pathology |
2 |
|
leukemia, t-cell - complications - drug therapy |
2 |
|
leukemia, t-cell - diagnosis - immunology - virology |
2 |
|
leukemia-free survival |
2 |
|
leukemia-lymphoma, adult t-cell - complications - genetics - therapy |
2 |
|
leukemia-lymphoma, adult t-cell - complications - therapy |
2 |
|
leukemia-lymphoma, adult t-cell - genetics - immunology |
2 |
|
leukemia-lymphoma, adult t-cell - genetics - pathology |
2 |
|
leukemia-lymphoma, adult t-cell - pathology - therapy |
2 |
|
leukemic infiltration |
2 |
|
leukocytes - pathology |
2 |
|
leukocytosis - blood |
2 |
|
leukocytosis - etiology |
2 |
|
liver neoplasms - diagnosis - pathology |
2 |
|
liver neoplasms - metabolism - pathology - secondary |
2 |
|
lupus erythematosus, systemic - complications |
2 |
|
lupus erythematosus, systemic - complications - drug therapy |
2 |
|
lupus nephritis - complications - physiopathology |
2 |
|
lymphocyte activation - genetics |
2 |
|
lymphohistiocytosis, hemophagocytic - blood - etiology |
2 |
|
lymphoma - classification - genetics - metabolism - pathology - radiography |
2 |
|
lymphoma - diagnosis - immunology - pathology |
2 |
|
lymphoma - drug therapy - physiopathology |
2 |
|
lymphoma - pathology - therapy |
2 |
|
lymphoma, b-cell - pathology |
2 |
|
lymphoma, extranodal nk-t-cell |
2 |
|
lymphoma, extranodal nk-t-cell - diagnosis - drug therapy - genetics - pathology |
2 |
|
lymphoma, extranodal nk-t-cell - diagnosis - drug therapy - pathology |
2 |
|
lymphoma, extranodal nk-t-cell - diagnosis - mortality - therapy |
2 |
|
lymphoma, follicular |
2 |
|
lymphoma, large b-cell, diffuse - diagnosis |
2 |
|
lymphoma, large b-cell, diffuse - pathology |
2 |
|
lymphoma, large b-cell, diffuse - pathology - virology |
2 |
|
lymphoma, non-hodgkin - mortality - pathology - therapy |
2 |
|
lymphoma, t-cell - blood - drug therapy - genetics - immunology - virology |
2 |
|
lymphoma, t-cell - complications - immunology |
2 |
|
lymphoma, t-cell - diagnosis - pathology |
2 |
|
lymphoma, t-cell - diagnosis - pathology - therapy |
2 |
|
lymphoma, t-cell - pathology - virology |
2 |
|
lymphoma, t-cell, cutaneous - complications - diagnosis |
2 |
|
lymphomas |
2 |
|
lymphoproliferative disorders - genetics - immunology - pathology |
2 |
|
male breast |
2 |
|
malignant lymphomas |
2 |
|
marrow necrosis |
2 |
|
mature t cell |
2 |
|
mediastinal neoplasms - genetics |
2 |
|
megakaryoblastic transformation |
2 |
|
megakaryocytes - metabolism - pathology |
2 |
|
megakaryocytic ploidy |
2 |
|
membrane glycoproteins - analysis |
2 |
|
metaphase |
2 |
|
minimal residual leukemia |
2 |
|
mir-155-3p |
2 |
|
mir-9-3 |
2 |
|
mirna |
2 |
|
mitoxantrone, therapeutic use |
2 |
|
mobilization |
2 |
|
molecular remission |
2 |
|
monitoring, physiologic |
2 |
|
monosomy |
2 |
|
monosomy - genetics |
2 |
|
monosomy 7 |
2 |
|
mrd-ve cr |
2 |
|
msp |
2 |
|
mucosa‐associated lymphoid tissue |
2 |
|
multidrug resistance |
2 |
|
muscle neoplasms - genetics - metabolism - pathology - radiography |
2 |
|
muscle, skeletal - metabolism - pathology - radiography |
2 |
|
mutagens |
2 |
|
mutation, missense |
2 |
|
mycosis fungoides |
2 |
|
mycosis fungoides - drug therapy - radiotherapy |
2 |
|
mycosis fungoides - genetics - pathology |
2 |
|
myeloblastic transformation |
2 |
|
myelodysplastic syndromes - complications - etiology - genetics |
2 |
|
myelodysplastic syndromes - genetics - metabolism - therapy |
2 |
|
myeloproliferative disorders (mpds) |
2 |
|
myeloproliferative disorders - complications - diagnosis - genetics |
2 |
|
myeloproliferative disorders - pathology |
2 |
|
myeloproliferative neoplasm |
2 |
|
myocardial infarction - pathology - physiopathology - surgery |
2 |
|
myocardial ischemia - therapy |
2 |
|
myocardium |
2 |
|
myocardium - pathology |
2 |
|
nasal |
2 |
|
nasopharyngeal neoplasms - chemically induced |
2 |
|
nasopharyngeal neoplasms - genetics - pathology |
2 |
|
nasopharynx |
2 |
|
natural killer t-cells - pathology |
2 |
|
necrosis |
2 |
|
neoplasm metastasis |
2 |
|
neoplasm recurrence, local - drug therapy |
2 |
|
neoplasm recurrence, local - genetics |
2 |
|
neoplasms - chemically induced |
2 |
|
neoplasms - complications - therapy |
2 |
|
neoplasms, multiple primary - genetics - pathology |
2 |
|
neoplasms, second primary - etiology - genetics |
2 |
|
neoplasms, unknown primary - complications - diagnosis |
2 |
|
neoplastic cells, circulating - pathology |
2 |
|
neurofibromatosis 1 - complications - genetics |
2 |
|
neutrophils - physiology |
2 |
|
newly diagnosed |
2 |
|
newly diagnosed acute promyelocytic leukemia |
2 |
|
nfκb |
2 |
|
nk cell lectin-like receptor subfamily d |
2 |
|
nk/t-cell lymphomas |
2 |
|
non-hsct |
2 |
|
non-nasal |
2 |
|
non‐hodgkin's lymphoma |
2 |
|
nose neoplasms - drug therapy - physiopathology |
2 |
|
nose neoplasms - mortality - pathology - therapy |
2 |
|
nose neoplasms - pathology - therapy |
2 |
|
nuclear proteins - genetics |
2 |
|
nucleic acid hybridization - methods |
2 |
|
o(6)-methylguanine-dna methyltransferase - genetics |
2 |
|
oral arsenic |
2 |
|
oral bioavailability |
2 |
|
osteosclerosis - blood - etiology - radiography - radionuclide imaging |
2 |
|
ovarian neoplasms - genetics |
2 |
|
ovary - cytology - physiology - ultrastructure |
2 |
|
oxides - administration & dosage - adverse effects - therapeutic use |
2 |
|
oxides - adverse effects - therapeutic use |
2 |
|
oxides - metabolism - pharmacokinetics - pharmacology |
2 |
|
p-glycoprotein - biosynthesis |
2 |
|
p15 methylation |
2 |
|
palatal neoplasms - diagnosis - drug therapy - pathology |
2 |
|
panniculitis - pathology |
2 |
|
paraganglioma - diagnosis - secondary |
2 |
|
paralyses, familial periodic - etiology |
2 |
|
paranasal sinus neoplasms - genetics |
2 |
|
pd-1 |
2 |
|
pediatric apl |
2 |
|
peritoneal diseases - metabolism - pathology |
2 |
|
peritonitis - etiology |
2 |
|
pet-ve cr |
2 |
|
ph + leukemia relapse |
2 |
|
pharmacokinetics |
2 |
|
phenotype |
2 |
|
pituitary apoplexy - etiology |
2 |
|
pituitary neoplasms - complications - secretion |
2 |
|
pituitary neoplasms - pathology |
2 |
|
plasma cells - pathology |
2 |
|
plasma dna |
2 |
|
platelet |
2 |
|
polymyositis - pathology |
2 |
|
polyomavirus infections - etiology - virology |
2 |
|
posaconazole |
2 |
|
post-transplant lymphoproliferative disease |
2 |
|
post-transplantation |
2 |
|
postoperative complications - immunology |
2 |
|
postrelapse survival |
2 |
|
precursor cell lymphoblastic leukemia-lymphoma - diagnosis - genetics |
2 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics - immunology |
2 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics - metabolism |
2 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics - pathology |
2 |
|
precursor cell lymphoblastic leukemia-lymphoma - pathology - therapy |
2 |
|
prednisolone - administration & dosage |
2 |
|
prednisone |
2 |
|
protein-tyrosine kinases - antagonists and inhibitors |
2 |
|
puva therapy - adverse effects |
2 |
|
pyrimidines - adverse effects - pharmacokinetics |
2 |
|
rapid deep responses |
2 |
|
rara |
2 |
|
rearrangement of 3q26 |
2 |
|
receptor protein-tyrosine kinases - genetics |
2 |
|
receptors, retinoic acid - genetics |
2 |
|
recipient origin |
2 |
|
red-cell aplasia, pure - blood - drug therapy |
2 |
|
red-cell aplasia, pure - complications - drug therapy |
2 |
|
reduced intensity conditioning |
2 |
|
regression analysis |
2 |
|
relapsed acute myeloid leukemia |
2 |
|
relapsed or refractory multiple myeloma |
2 |
|
repressor proteins - genetics |
2 |
|
retinoblastoma protein - genetics |
2 |
|
reverse transcription‐polymerase chain reaction |
2 |
|
rheumatic-fever-complications |
2 |
|
rna, messenger - drug effects - metabolism |
2 |
|
romiplostim |
2 |
|
rupture, spontaneous |
2 |
|
safety |
2 |
|
secondary malignancies |
2 |
|
sepsis - etiology |
2 |
|
sequence alignment |
2 |
|
sexually transmitted diseases, viral - immunology - transmission - virology |
2 |
|
sezary syndrome - genetics - pathology |
2 |
|
shp1 |
2 |
|
simian virus 40 - genetics |
2 |
|
skin diseases - metabolism - pathology |
2 |
|
skin diseases, bacterial - diagnosis |
2 |
|
skin neoplasms - diagnosis |
2 |
|
skin neoplasms - drug therapy - pathology |
2 |
|
skin neoplasms - genetics - pathology |
2 |
|
socs1 |
2 |
|
sphenoid sinus |
2 |
|
spinal cord compression - etiology |
2 |
|
splenic neoplasms - diagnosis - pathology |
2 |
|
splenic rupture - etiology - surgery |
2 |
|
spondylitis, ankylosing - genetics |
2 |
|
status quo |
2 |
|
stereotyped receptors |
2 |
|
sti571 |
2 |
|
stomach neoplasms - etiology - pathology |
2 |
|
stomach neoplasms - genetics - metabolism |
2 |
|
streptococcal-infections-complications |
2 |
|
subarachnoid hemorrhage - diagnosis |
2 |
|
subclavian vein - radiography |
2 |
|
survivors |
2 |
|
syndrome |
2 |
|
sézary syndrome |
2 |
|
t cell lymphoma, treatment |
2 |
|
t(8;21) |
2 |
|
t-cell lymphomas |
2 |
|
t-lymphocytes, cytotoxic - immunology |
2 |
|
t-mds |
2 |
|
tetraarsenic tetrasulfide |
2 |
|
therapy-related acute myeloid leukaemia/myelodysplasia |
2 |
|
thiamine |
2 |
|
thiamine - administration & dosage - blood |
2 |
|
thrombocythemia, essential - complications - genetics - therapy |
2 |
|
thrombocythemia, essential - complications - pathology |
2 |
|
thrombocythemia, essential - genetics |
2 |
|
thrombocytopenia - etiology |
2 |
|
thromboembolism - epidemiology - ethnology - genetics |
2 |
|
thrombophlebitis - etiology - genetics |
2 |
|
thyrotoxic periodic paralysis |
2 |
|
thyrotoxicosis - etiology |
2 |
|
tomography, emission-computed, single-photon |
2 |
|
trans-activators - metabolism |
2 |
|
translocation, genetic - physiology |
2 |
|
transplantation conditioning - adverse effects |
2 |
|
transplantation conditioning - methods - standards |
2 |
|
tretinoin - pharmacology |
2 |
|
triploidy |
2 |
|
trisomy - genetics |
2 |
|
tuberculosis - blood - complications |
2 |
|
tumor markers, biological - genetics - metabolism |
2 |
|
tumor suppressive microrna |
2 |
|
tumor virus infections - immunology - virology |
2 |
|
tumor virus infections - pathology |
2 |
|
u937 cells |
2 |
|
umbilical cord blood |
2 |
|
unsustained cr |
2 |
|
up-regulation - drug effects |
2 |
|
uterine cervical neoplasms - genetics |
2 |
|
vegetables |
2 |
|
ventriculostomy |
2 |
|
viral matrix proteins - genetics |
2 |
|
viremia - complications - drug therapy |
2 |
|
x chromosome inactivation |
2 |
|
5q—syndrome |
1 |
|
aberrant promoter methylation |
1 |
|
actins - metabolism |
1 |
|
acute promyelocytic leukaemia (apl) |
1 |
|
adam proteins - immunology |
1 |
|
adenocarcinoma - pathology - secondary |
1 |
|
adenoviral vectors |
1 |
|
adenoviridae - genetics |
1 |
|
adenoviruses, human |
1 |
|
adipose tissue - pathology |
1 |
|
age of onset |
1 |
|
aging - drug effects |
1 |
|
al amyloidosis |
1 |
|
allogenic hematopoietic stem cell transplantation |
1 |
|
alpha-thalassemia - complications |
1 |
|
alternative splicing |
1 |
|
amino acid sequence |
1 |
|
amphotericin b - therapeutic use |
1 |
|
amyloid - metabolism |
1 |
|
amyloid neuropathies, familial - pathology |
1 |
|
amyloidosis - diagnosis - epidemiology - therapy |
1 |
|
anaphase |
1 |
|
anaplastic large cell lymphoma |
1 |
|
anemia - etiology |
1 |
|
anemia, aplastic - complications - therapy |
1 |
|
anemia, megaloblastic - chemically induced |
1 |
|
anemia, refractory - genetics - pathology |
1 |
|
antifungal agents - administration & dosage - adverse effects - pharmacology |
1 |
|
antigens, cd |
1 |
|
antigens, cd - analysis - biosynthesis |
1 |
|
antigens, cd - genetics |
1 |
|
antigens, cd20 - analysis |
1 |
|
antigens, cd4 |
1 |
|
antigens, cd56 |
1 |
|
antigens, neoplasm |
1 |
|
antineoplastic agents - administration & dosage - adverse effects - pharmacology - therapeutic use |
1 |
|
antineoplastic agents - administration & dosage - adverse effects - toxicity |
1 |
|
antineoplastic agents - administration & dosage - pharmacokinetics - pharmacology - therapeutic use |
1 |
|
antineoplastic agents - administration & dosage - pharmacology - therapeutic use |
1 |
|
antineoplastic agents - administration & dosage - therapeutic use |
1 |
|
antineoplastic combined chemotherapy protocols - standards - therapeutic use |
1 |
|
antitumor pharmacology |
1 |
|
aquired factor viii inhibitor |
1 |
|
arsenic - blood - cerebrospinal fluid |
1 |
|
arsenic - cerebrospinal fluid |
1 |
|
arsenic - urine |
1 |
|
arsenic poisoning |
1 |
|
arsenic poisoning - complications - urine |
1 |
|
arsenicals |
1 |
|
arsenicals - administration & dosage - adverse effects |
1 |
|
arsenicals - administration & dosage - adverse effects - pharmacology - therapeutic use |
1 |
|
arsenicals - administration & dosage - pharmacokinetics - pharmacology - therapeutic use |
1 |
|
arsenicals - administration & dosage - pharmacokinetics - therapeutic use |
1 |
|
arsenicals - pharmacology |
1 |
|
asciminib |
1 |
|
ascites - etiology |
1 |
|
ascorbic acid - administration & dosage - adverse effects |
1 |
|
asia - epidemiology |
1 |
|
asparaginase - administration & dosage - therapeutic use |
1 |
|
aspergillosis - drug therapy - radiography |
1 |
|
autoantigens - blood |
1 |
|
autoimmune diseases - drug therapy |
1 |
|
azathioprine - adverse effects - immunology |
1 |
|
azathioprine - adverse effects - therapeutic use |
1 |
|
b-lymphocytes - classification |
1 |
|
b-lymphocytes - pathology |
1 |
|
base sequence - genetics |
1 |
|
basophils - pathology |
1 |
|
benzene - adverse effects |
1 |
|
beta-galactosidase - metabolism |
1 |
|
biological markers - blood |
1 |
|
biopsy - methods |
1 |
|
blast crisis - genetics - pathology |
1 |
|
blastic transformation |
1 |
|
blood cell count |
1 |
|
blood coagulation tests |
1 |
|
blood group incompatibility - complications |
1 |
|
bone marrow - pathology - ultrastructure |
1 |
|
bone marrow cells - metabolism - pathology |
1 |
|
bone neoplasms |
1 |
|
boronic acids - administration & dosage - therapeutic use |
1 |
|
brain diseases - drug therapy - microbiology |
1 |
|
brain neoplasms - pathology |
1 |
|
brain neoplasms - secondary |
1 |
|
breast neoplasms - metabolism |
1 |
|
burkitt lymphoma - genetics |
1 |
|
ca-125 antigen - blood |
1 |
|
caenorhabditis elegans - genetics |
1 |
|
calibration |
1 |
|
carcinoma, bronchogenic - complications |
1 |
|
carcinoma, signet ring cell - pathology |
1 |
|
carcinoma, squamous cell |
1 |
|
carcinoma, squamous cell - etiology - surgery |
1 |
|
carcinoma, squamous cell - pathology |
1 |
|
cardiac amyloidosis |
1 |
|
cardiomyopathies - diagnosis - epidemiology - therapy |
1 |
|
causality |
1 |
|
caveolin 1 |
1 |
|
caveolin-1 |
1 |
|
caveolins - biosynthesis - genetics |
1 |
|
cd38 |
1 |
|
cell differentiation - drug effects |
1 |
|
cell division - drug effects |
1 |
|
cell line, tumor - ultrastructure |
1 |
|
cell lineage |
1 |
|
central nervous system - chemistry |
1 |
|
cerebral aspergillosis |
1 |
|
cerebrospinal fluid - cytology |
1 |
|
cerebrospinal fluid monocytosis. |
1 |
|
charcot‐leyden crystal |
1 |
|
chickenpox |
1 |
|
chlorambucil - adverse effects |
1 |
|
chromosome aberrations - pathology |
1 |
|
chromosome breakage |
1 |
|
chromosomes, artificial, bacterial |
1 |
|
chromosomes, human, pair 11 - genetics |
1 |
|
chromosomes, human, pair 14 - genetics |
1 |
|
chromosomes, human, pair 16 |
1 |
|
chromosomes, human, pair 18 |
1 |
|
chromosomes, human, pair 2 - ultrastructure |
1 |
|
chromosomes, human, pair 22 |
1 |
|
chromosomes, human, pair 3 - genetics |
1 |
|
chromosomes, human, pair 3 - ultrastructure |
1 |
|
chromosomes, human, pair 5 - genetics |
1 |
|
chromosomes, human, pair 6 |
1 |
|
chromosomes, human, pair 6 - genetics |
1 |
|
chromosomes, human, pair 7 - genetics |
1 |
|
chronic idiopathic myelofibrosis |
1 |
|
chronic myeloid leukaemia |
1 |
|
clinical trial |
1 |
|
clinical trials as topic |
1 |
|
clone cells - pathology |
1 |
|
cluster analysis |
1 |
|
congestive heart failure |
1 |
|
congresses as topic |
1 |
|
coordinate gene regulation |
1 |
|
cord blood stem cell transplantation |
1 |
|
cord lesion |
1 |
|
corticosteroids |
1 |
|
cost effectiveness analysis |
1 |
|
cpg islands - genetics |
1 |
|
creb-binding protein - genetics |
1 |
|
cyclic amp response element-binding protein - metabolism |
1 |
|
cyclin-dependent kinase inhibitor p16 |
1 |
|
cyclophosphamide - adverse effects - therapeutic use |
1 |
|
cytarabine - administration & dosage - adverse effects - toxicity |
1 |
|
cytarabine - therapeutic use |
1 |
|
cytogenetic analysis |
1 |
|
cytokine gene |
1 |
|
cytomegalovirus-infections-complications |
1 |
|
cytosine |
1 |
|
cytosine arabinoside |
1 |
|
daratumumab |
1 |
|
darinaparsin |
1 |
|
dehydroepiandrosterone - administration & dosage - adverse effects |
1 |
|
del(3) |
1 |
|
del(6q) |
1 |
|
demyelination |
1 |
|
dengue - complications |
1 |
|
developing countries - economics |
1 |
|
dexamethasone - administration & dosage - therapeutic use |
1 |
|
dexamethasone - therapeutic use |
1 |
|
disseminated mycobacterial infection |
1 |
|
dna repair |
1 |
|
dna, recombinant |
1 |
|
donor leukaemia |
1 |
|
dosage compensation, genetic |
1 |
|
down syndrome - complications - immunology |
1 |
|
down syndrome - genetics |
1 |
|
down's syndrome |
1 |
|
down-regulation - drug effects |
1 |
|
drug administration schedule |
1 |
|
drug delivery systems |
1 |
|
drug design |
1 |
|
drug therapy |
1 |
|
drug therapy, combination |
1 |
|
dyspepsia - chemically induced |
1 |
|
dysplastic eosinophils |
1 |
|
echocardiography |
1 |
|
enchondromatosis - complications - radiography - surgery |
1 |
|
endocarditis - complications - pathology |
1 |
|
enzyme activation - drug effects |
1 |
|
enzyme inhibitors - adverse effects |
1 |
|
eosinophilia - pathology |
1 |
|
epstein-barr virus infections - pathology - virology |
1 |
|
erythroid-specific dna-binding factors |
1 |
|
erythropoiesis - genetics |
1 |
|
erythropoiesis - physiology |
1 |
|
esophageal neoplasms - pathology |
1 |
|
etoposide - administration & dosage - therapeutic use |
1 |
|
evidence-based medicine |
1 |
|
exfoliative cytology |
1 |
|
factor vii - genetics |
1 |
|
factor vii deficiency |
1 |
|
factor vii deficiency - genetics |
1 |
|
factor x - genetics |
1 |
|
factor x deficiency - genetics |
1 |
|
factor x gene mutation |
1 |
|
factor xi - genetics |
1 |
|
factor xi deficiency |
1 |
|
factor xi deficiency - blood - genetics |
1 |
|
false negative reactions |
1 |
|
fingers |
1 |
|
flucytosine - therapeutic use |
1 |
|
fluorescence in situ hybridization |
1 |
|
fragile x mental retardation protein |
1 |
|
fragile x syndrome - complications - genetics |
1 |
|
frameshift mutation |
1 |
|
fusion proteins, bcr-abl - analysis - genetics |
1 |
|
fusion proteins, bcr-abl - blood |
1 |
|
gangrene - complications |
1 |
|
gene components |
1 |
|
gene deletion |
1 |
|
gene expression profiling - methods |
1 |
|
gene expression regulation, neoplastic - physiology |
1 |
|
gene fusion |
1 |
|
gene regulatory networks |
1 |
|
gene therapy - methods |
1 |
|
gene transfer |
1 |
|
gene vectors |
1 |
|
genes, homeobox - genetics |
1 |
|
genes, myc |
1 |
|
genes, reporter |
1 |
|
genes, synthetic |
1 |
|
genes, t-cell receptor beta |
1 |
|
genetic diseases, x-linked - epidemiology - genetics |
1 |
|
genetic engineering |
1 |
|
genetic therapy |
1 |
|
genetic vectors |
1 |
|
genetics, medical |
1 |
|
genital neoplasms, male - complications - secondary |
1 |
|
genome |
1 |
|
genome-wide association study |
1 |
|
giant lymph node hyperplasia - complications |
1 |
|
glutathione s-transferase pi |
1 |
|
glutathione transferase - genetics |
1 |
|
glycoproteins - analysis |
1 |
|
graft rejection - prevention & control |
1 |
|
graft vs host disease - complications |
1 |
|
granulocyte colony-stimulating factor |
1 |
|
granulocyte colony-stimulating factor - adverse effects |
1 |
|
granulocyte-macrophage colony-stimulating factor - adverse effects |
1 |
|
granulocytes - physiology |
1 |
|
growth inhibitors - pharmacology |
1 |
|
guanine |
1 |
|
guillain-barre syndrome - complications - diagnosis |
1 |
|
head and neck neoplasms |
1 |
|
headache - chemically induced |
1 |
|
health services accessibility |
1 |
|
healthcare disparities |
1 |
|
heart catheterization |
1 |
|
heart transplantation |
1 |
|
hematologic diseases - etiology |
1 |
|
hematologic neoplasms - chemically induced |
1 |
|
hematologic neoplasms - drug therapy |
1 |
|
hematologic neoplasms - drug therapy - pathology |
1 |
|
hematoma |
1 |
|
hematopoietic cell growth factors - genetics |
1 |
|
hematopoietic stem-cell transplantation |
1 |
|
hemoglobinuria, paroxysmal - blood - complications - genetics |
1 |
|
hemoglobinuria, paroxysmal - chemically induced |
1 |
|
hemoglobinuria, paroxysmal - epidemiology - physiopathology |
1 |
|
hemolysis - genetics |
1 |
|
hemophilia a - drug therapy |
1 |
|
hemorrhage - drug therapy |
1 |
|
hemorrhage-complications |
1 |
|
hepatitis b - blood - complications - therapy |
1 |
|
hepatitis b, chronic - complications - immunology |
1 |
|
hereditary diseases |
1 |
|
herpes zoster - chemically induced - epidemiology |
1 |
|
herpes zoster - diagnosis |
1 |
|
herpesvirus 3, human |
1 |
|
heterozygote |
1 |
|
histiocytosis, langerhans-cell - pathology - therapy |
1 |
|
histone acetyltransferases - genetics |
1 |
|
homeodomain proteins - genetics |
1 |
|
homeodomain proteins - genetics - physiology |
1 |
|
hormone replacement therapy - adverse effects |
1 |
|
hospitals, special |
1 |
|
human growth hormone - administration & dosage - adverse effects |
1 |
|
hydroxyurea - adverse effects |
1 |
|
hyperpigmentation - chemically induced |
1 |
|
hypertrichosis - etiology |
1 |
|
ifosfamide - administration & dosage - therapeutic use |
1 |
|
immunoenzyme techniques |
1 |
|
immunoglobulin class switching |
1 |
|
immunologic factors - therapeutic use |
1 |
|
immunosuppressive agents - adverse effects - immunology |
1 |
|
imr-32 |
1 |
|
indoles - pharmacology |
1 |
|
inhibitor of apoptosis proteins |
1 |
|
injections, spinal |
1 |
|
intercellular signaling peptides and proteins - metabolism |
1 |
|
interferon-alpha - therapeutic use |
1 |
|
interleukin-2 - genetics |
1 |
|
interleukin-3 |
1 |
|
intrathecal chemotherapy |
1 |
|
intravenous |
1 |
|
inv(14) |
1 |
|
inv(7) |
1 |
|
isochromosomes |
1 |
|
isochromosomes - genetics |
1 |
|
isoenzymes - genetics |
1 |
|
janus kinase 2 - genetics - metabolism |
1 |
|
japanese subgroup analysis |
1 |
|
kaposi's sarcoma |
1 |
|
ketoconazole |
1 |
|
ketoconazole - administration & dosage - therapeutic use |
1 |
|
kidney - pathology |
1 |
|
kidney neoplasms |
1 |
|
kidney transplantation - adverse effects |
1 |
|
killer cells, natural - metabolism - pathology |
1 |
|
kshv |
1 |
|
laparotomy |
1 |
|
large granular lymphocyte leukaemia |
1 |
|
leptin - metabolism |
1 |
|
letermovir |
1 |
|
lethal dose 50 |
1 |
|
leukemia - classification - diagnosis - therapy |
1 |
|
leukemia - diagnosis - mortality - pathology - therapy |
1 |
|
leukemia - diagnosis - therapy |
1 |
|
leukemia - drug therapy |
1 |
|
leukemia - drug therapy - etiology - pathology |
1 |
|
leukemia - enzymology - genetics - pathology - surgery |
1 |
|
leukemia - etiology - genetics |
1 |
|
leukemia - pathology - therapy |
1 |
|
leukemia, erythroblastic, acute - blood - genetics |
1 |
|
leukemia, erythroblastic, acute - genetics - metabolism - pathology |
1 |
|
leukemia, hairy cell - blood - genetics |
1 |
|
leukemia, large granular lymphocytic - drug therapy - etiology |
1 |
|
leukemia, lymphocytic, chronic, b-cell - blood - genetics - pathology |
1 |
|
leukemia, lymphocytic, chronic, b-cell - drug therapy |
1 |
|
leukemia, lymphoid |
1 |
|
leukemia, lymphoid - drug therapy - prevention & control |
1 |
|
leukemia, megakaryoblastic, acute - complications - pathology |
1 |
|
leukemia, monocytic, acute - pathology |
1 |
|
leukemia, monocytic, acute - urine |
1 |
|
leukemia, myelogenous, chronic, bcr-abl positive - blood - complications |
1 |
|
leukemia, myelogenous, chronic, bcr-abl positive - blood - complications - therapy |
1 |
|
leukemia, myelogenous, chronic, bcr-abl positive - blood - drug therapy - enzymology |
1 |
|
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis - therapy |
1 |
|
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy |
1 |
|
leukemia, myelogenous, chronic, bcr-abl positive - etiology |
1 |
|
leukemia, myelogenous, chronic, bcr-abl positive - genetics - pathology - therapy |
1 |
|
leukemia, myeloid - chemically induced - genetics - pathology |
1 |
|
leukemia, myeloid - complications |
1 |
|
leukemia, myeloid - complications - pathology |
1 |
|
leukemia, myeloid - etiology - virology |
1 |
|
leukemia, myeloid - pathology |
1 |
|
leukemia, myeloid - surgery |
1 |
|
leukemia, myeloid, acute - complications - diagnosis - drug therapy |
1 |
|
leukemia, myeloid, acute - diagnosis - genetics |
1 |
|
leukemia, myeloid, acute - drug therapy - genetics |
1 |
|
leukemia, myeloid, acute - epidemiology - etiology |
1 |
|
leukemia, myeloid, acute - genetics - immunology |
1 |
|
leukemia, myeloid, acute - genetics - physiopathology |
1 |
|
leukemia, myeloid, chronic, atypical, bcr-abl negative - etiology |
1 |
|
leukemia, neutrophilic, chronic - pathology |
1 |
|
leukemia, plasma cell - drug therapy - immunology - pathology |
1 |
|
leukemia, prolymphocytic, t-cell - etiology - genetics - pathology |
1 |
|
leukemia, promyelocytic, acute - blood - cerebrospinal fluid - drug therapy |
1 |
|
leukemia, promyelocytic, acute - blood - complications - therapy |
1 |
|
leukemia, promyelocytic, acute - etiology |
1 |
|
leukemia, promyelocytic, acute - genetics |
1 |
|
leukemia, t-cell - complications - ethnology - pathology |
1 |
|
leukemia, t-cell - diagnosis |
1 |
|
leukemia, t-cell - etiology - pathology |
1 |
|
leukemia, t-cell - genetics |
1 |
|
leukemia, t-cell - genetics - pathology |
1 |
|
leukemia-lymphoma, adult t-cell - etiology - genetics - pathology |
1 |
|
leukemoid reaction |
1 |
|
leukemoid reaction - diagnosis - microbiology |
1 |
|
leukocytes, mononuclear - ultrastructure |
1 |
|
liver cirrhosis - metabolism - pathology |
1 |
|
liver diseases - microbiology - pathology |
1 |
|
liver failure - blood - therapy |
1 |
|
liver metastases |
1 |
|
liver neoplasms, experimental - secondary - therapy |
1 |
|
liver transplantation - methods |
1 |
|
long-term safety |
1 |
|
lung cancer |
1 |
|
lung neoplasms - complications |
1 |
|
lung neoplasms - genetics |
1 |
|
lung transplantation - immunology |
1 |
|
lung-diseases-complications |
1 |
|
lupus-erythematosus,-systemic-complications |
1 |
|
lymph nodes - pathology |
1 |
|
lymphatic diseases - etiology |
1 |
|
lymphocyte activation |
1 |
|
lymphocytes - cytology |
1 |
|
lymphocytes - pathology - ultrastructure |
1 |
|
lymphoma - classification - diagnosis - genetics - pathology |
1 |
|
lymphoma - classification - diagnosis - therapy |
1 |
|
lymphoma - diagnosis - mortality - pathology - therapy |
1 |
|
lymphoma - diagnosis - therapy |
1 |
|
lymphoma - pathology |
1 |
|
lymphoma, aids-related - pathology - virology |
1 |
|
lymphoma, b-cell - blood - genetics - pathology |
1 |
|
lymphoma, b-cell - complications - pathology |
1 |
|
lymphoma, b-cell - drug therapy |
1 |
|
lymphoma, b-cell - drug therapy - genetics - pathology - radiotherapy |
1 |
|
lymphoma, b-cell - pathology - virology |
1 |
|
lymphoma, extranodal nk-t-cell - diagnosis - genetics - metabolism - therapy |
1 |
|
lymphoma, extranodal nk-t-cell - diagnosis - mortality - pathology - therapy |
1 |
|
lymphoma, extranodal nk-t-cell - drug therapy - mortality - pathology |
1 |
|
lymphoma, extranodal nk-t-cell - drug therapy - pathology - therapy |
1 |
|
lymphoma, extranodal nk-t-cell - drug therapy - prevention & control |
1 |
|
lymphoma, extranodal nk-t-cell - epidemiology - pathology - therapy |
1 |
|
lymphoma, extranodal nk-t-cell - genetics - immunology - metabolism - pathology |
1 |
|
lymphoma, extranodal nk-t-cell - pathology - therapy |
1 |
|
lymphoma, large-cell, anaplastic - diagnosis - enzymology |
1 |
|
lymphoma, non-hodgkin - diagnosis - drug therapy - genetics |
1 |
|
lymphoma, t-cell - diagnosis - genetics - pathology |
1 |
|
lymphoma, t-cell - diagnosis - mortality - pathology - therapy |
1 |
|
lymphoma, t-cell - genetics |
1 |
|
lymphoma, t-cell - pathology - surgery |
1 |
|
lymphoma, t-cell, cutaneous - drug therapy - pathology |
1 |
|
lymphoma, t-cell, cutaneous - epidemiology - pathology - therapy |
1 |
|
lymphoproliferative disorders |
1 |
|
lymphoproliferative disorders - complications - diagnosis |
1 |
|
lymphoproliferative disorders - diagnosis - etiology - therapy - virology |
1 |
|
lymphoproliferative disorders - diagnosis - genetics - metabolism - therapy |
1 |
|
lymphoproliferative disorders - etiology - pathology |
1 |
|
lysophospholipase |
1 |
|
mastocytosis |
1 |
|
mastocytosis - complications - drug therapy |
1 |
|
mdr-1 |
1 |
|
mds |
1 |
|
mediastinal b cell lymphoma |
1 |
|
mediastinal neoplasms - drug therapy - genetics - pathology - radiotherapy |
1 |
|
medical oncology - economics - standards |
1 |
|
megakaryoblastic leukemia |
1 |
|
megakaryocytes - pathology |
1 |
|
membrane proteins - genetics - metabolism |
1 |
|
meningeal neoplasms - blood - cerebrospinal fluid - drug therapy - secondary |
1 |
|
meningitis - pathology |
1 |
|
meningitis, aseptic - pathology |
1 |
|
metabolism - pathology - surgery |
1 |
|
methotrexate - administration & dosage - adverse effects - toxicity |
1 |
|
methotrexate - administration & dosage - therapeutic use |
1 |
|
microarray analysis |
1 |
|
microcirculation |
1 |
|
microsatellite repeats |
1 |
|
microscopy, electron |
1 |
|
microtubule-associated proteins - antagonists & inhibitors - metabolism - physiology |
1 |
|
mixed connective tissue disease - blood - complications - diagnosis |
1 |
|
mixed connective tissue disease - complications - diagnosis |
1 |
|
molecular prognostic markers |
1 |
|
molecular targeted therapy |
1 |
|
monocytes - pathology |
1 |
|
multigene family |
1 |
|
muramidase - urine |
1 |
|
mutation - genetics |
1 |
|
myc |
1 |
|
mycobacterium infections - complications - diagnosis |
1 |
|
myelodysplastic syndromes - chemically induced - complications - genetics |
1 |
|
myelodysplastic syndromes - chemically induced - genetics |
1 |
|
myelodysplastic syndromes - complications - diagnosis - genetics |
1 |
|
myelodysplastic syndromes - complications - genetics |
1 |
|
myelodysplastic syndromes - diagnosis - genetics |
1 |
|
myelodysplastic syndromes - etiology - genetics - pathology |
1 |
|
myelodysplastic syndromes - etiology - pathology |
1 |
|
myelodysplastic syndromes - genetics - therapy |
1 |
|
myelodysplastic syndromes - pathology |
1 |
|
myeloid-lymphoid leukemia protein |
1 |
|
myeloid-lymphoid leukemia protein - genetics |
1 |
|
myeloproliferative disorders - complications - diagnosis |
1 |
|
myeloproliferative disorders - complications - immunology |
1 |
|
nail diseases - chemically induced |
1 |
|
nasopharyngeal neoplasms - diagnosis - pathology |
1 |
|
natural kille-cell lymphoma |
1 |
|
natural killer cell leukemia |
1 |
|
neonatal leukemia |
1 |
|
neoplasm proteins - metabolism |
1 |
|
neoplasms - therapy |
1 |
|
neoplasms, experimental - therapy |
1 |
|
neoplasms, multiple primary - genetics |
1 |
|
neoplasms, multiple primary - pathology |
1 |
|
neoplasms, plasma cell - complications - drug therapy |
1 |
|
neoplasms, second primary - chemically induced - genetics - pathology |
1 |
|
neoplasms, second primary - etiology - surgery |
1 |
|
nephrolithiasis - chemically induced |
1 |
|
nephrotic syndrome - etiology |
1 |
|
nerve tissue proteins - genetics |
1 |
|
nervous system diseases - chemically induced - pathology |
1 |
|
neuroblastoma - enzymology - metabolism - pathology |
1 |
|
neuroblastoma - pathology |
1 |
|
neurofibromatosis |
1 |
|
neurofilament proteins - metabolism |
1 |
|
neurons - drug effects |
1 |
|
neurons - drug effects - metabolism - pathology |
1 |
|
non-nasal aggressive |
1 |
|
nonmyeloablative hematopoietic stem cell transplantation |
1 |
|
nonsense mutation |
1 |
|
noonan syndrome |
1 |
|
noonan syndrome - diagnosis - genetics |
1 |
|
nordihydroguaiaretic acid - analogs & derivatives - pharmacology |
1 |
|
nose neoplasms - diagnosis - genetics - pathology |
1 |
|
nose neoplasms - drug therapy - pathology |
1 |
|
nose neoplasms - etiology - pathology - therapy - virology |
1 |
|
nose neoplasms - genetics |
1 |
|
nose neoplasms - genetics - immunology - metabolism - pathology |
1 |
|
nuclear pore complex proteins |
1 |
|
obesity - metabolism |
1 |
|
occupational diseases - chemically induced |
1 |
|
occupational diseases - etiology |
1 |
|
oesophagus |
1 |
|
olliers' disease |
1 |
|
oncogenes - physiology |
1 |
|
oxides - administration & dosage - adverse effects |
1 |
|
oxides - administration & dosage - adverse effects - pharmacology - therapeutic use |
1 |
|
oxides - administration & dosage - pharmacokinetics - pharmacology - therapeutic use |
1 |
|
oxides - administration & dosage - pharmacokinetics - therapeutic use |
1 |
|
oxides - pharmacology |
1 |
|
p-glycoprotein - biosynthesis - genetics |
1 |
|
p53 |
1 |
|
pancytopenia |
1 |
|
panniculitis - drug therapy - pathology |
1 |
|
paraffin-embedded tissue |
1 |
|
paraneoplastic syndromes - etiology |
1 |
|
partial trisomy 1 |
1 |
|
pedigree |
1 |
|
pelvic neoplasms - drug therapy - immunology - pathology |
1 |
|
pentamidine - administration & dosage - adverse effects - pharmacology |
1 |
|
peritoneal dialysis, continuous ambulatory |
1 |
|
petroleum - adverse effects |
1 |
|
phagocytosis - physiology |
1 |
|
phenylalanine |
1 |
|
phenylalanine - genetics - metabolism |
1 |
|
philadelphia chromosome negative |
1 |
|
philadelphia negative |
1 |
|
phosphorus radioisotopes - therapeutic use |
1 |
|
piperazines - therapeutic use - toxicity |
1 |
|
pkc |
1 |
|
plasma exchange |
1 |
|
plasmacytoma |
1 |
|
plasmacytoma - diagnosis |
1 |
|
plasmacytoma - drug therapy - immunology - pathology - physiopathology |
1 |
|
pleural effusion |
1 |
|
pleural effusion, malignant - diagnosis - enzymology |
1 |
|
pleural effusion, malignant - etiology |
1 |
|
pleural effusion, malignant - pathology |
1 |
|
pleural neoplasms - pathology - secondary |
1 |
|
pneumonia, pneumocystis - drug therapy |
1 |
|
pneumonia,-viral-complications |
1 |
|
pnh |
1 |
|
polycythemia - chemically induced |
1 |
|
polycythemia vera - complications - therapy |
1 |
|
polymerase chain reaction - standards |
1 |
|
polymorphism, restriction fragment length |
1 |
|
ponatinib |
1 |
|
porphyria cutanea tarda - complications |
1 |
|
porphyrias - chemically induced |
1 |
|
porphyrins - metabolism |
1 |
|
posttransplantation lymphoproliferative disease |
1 |
|
precursor cell lymphoblastic leukemia-lymphoma - diagnosis - genetics - pathology |
1 |
|
preleukemia - drug therapy - ethnology - genetics - pathology |
1 |
|
primary effusion lymphoma |
1 |
|
primary myelofibrosis - complications - pathology |
1 |
|
prodrugs |
1 |
|
prodrugs - administration & dosage - therapeutic use |
1 |
|
proliferation |
1 |
|
protein kinase c - antagonists & inhibitors - metabolism |
1 |
|
protein-tyrosine kinases - antagonists & inhibitors - genetics |
1 |
|
proteinuria - etiology |
1 |
|
proto-oncogene proteins c-ets |
1 |
|
proto-oncogene proteins c-myc - metabolism |
1 |
|
proto-oncogenes |
1 |
|
pulmonary fibrosis - complications - drug therapy - genetics |
1 |
|
pulmonary stenosis |
1 |
|
pyrazines - administration & dosage - therapeutic use |
1 |
|
pyrimidines - administration & dosage - therapeutic use - toxicity |
1 |
|
radiation |
1 |
|
radiation dosage |
1 |
|
radiotherapy - adverse effects |
1 |
|
radiotherapy, adjuvant |
1 |
|
rar |
1 |
|
receptor protein-tyrosine kinases |
1 |
|
receptor, trka - metabolism |
1 |
|
receptor, trkb - metabolism |
1 |
|
receptors, antigen, t-cell - analysis - biosynthesis - classification |
1 |
|
receptors, antigen, t-cell, alpha-beta - genetics |
1 |
|
receptors, immunologic - immunology |
1 |
|
receptors, kir |
1 |
|
receptors, retinoic acid - drug effects - metabolism |
1 |
|
recombinant adenoviral vectors |
1 |
|
recombinant fusion proteins - genetics |
1 |
|
recombinant proteins |
1 |
|
rectal neoplasms - pathology |
1 |
|
recurrent aseptic meningitis |
1 |
|
red-cell aplasia, pure - drug therapy |
1 |
|
red-cell aplasia, pure - drug therapy - ethnology - genetics - pathology |
1 |
|
red-cell aplasia, pure - etiology |
1 |
|
red-cell aplasia, pure - etiology - therapy |
1 |
|
reference standards |
1 |
|
remission, spontaneous |
1 |
|
repetitive sequences, nucleic acid |
1 |
|
repetitive sequences, nucleic acid - genetics |
1 |
|
repressor proteins |
1 |
|
retinoic acid |
1 |
|
retinoic acid receptor |
1 |
|
retinoid x receptor |
1 |
|
retinoid x receptors |
1 |
|
rna, viral - blood |
1 |
|
rna-binding proteins |
1 |
|
rxr |
1 |
|
sarcoma, kaposi - pathology - virology |
1 |
|
sarcoma, kaposi - virology |
1 |
|
scleromyxedema - drug therapy - etiology - pathology |
1 |
|
scrotum |
1 |
|
sequence analysis, dna |
1 |
|
side effects |
1 |
|
signal transduction - drug effects - physiology |
1 |
|
signal transduction - genetics - physiology |
1 |
|
signet ring cell |
1 |
|
simplexvirus - isolation & purification |
1 |
|
skin neoplasms |
1 |
|
skin neoplasms - complications - secondary |
1 |
|
skin neoplasms - drug therapy - therapy |
1 |
|
skin neoplasms - genetics |
1 |
|
skin neoplasms - secondary |
1 |
|
skin ulcer - complications |
1 |
|
smoking - adverse effects |
1 |
|
solvents - adverse effects |
1 |
|
south america - epidemiology |
1 |
|
splenic diseases - microbiology - pathology |
1 |
|
spontaneous remission |
1 |
|
squamous cell carcinoma |
1 |
|
stereoisomerism |
1 |
|
subcutaneous panniculitis-like t-cell lymphoma |
1 |
|
suicide gene |
1 |
|
survivin |
1 |
|
t lymphoblastic lymphoma |
1 |
|
t(8;16) |
1 |
|
t(l;7) and trisomy 8 |
1 |
|
t-aml |
1 |
|
t-cell large granular lymphocyte leuekemia |
1 |
|
t-lymphocyte subsets |
1 |
|
t-lymphocytes - metabolism - pathology |
1 |
|
testosterone - administration & dosage - adverse effects |
1 |
|
tetrahydrofolate dehydrogenase - drug effects |
1 |
|
thalidomide - administration & dosage - therapeutic use |
1 |
|
therapy related myelodysplasia |
1 |
|
third line |
1 |
|
thrombocythemia, essential - enzymology - genetics - pathology - surgery |
1 |
|
thrombocytosis - blood - etiology |
1 |
|
thrombocytosis - drug therapy |
1 |
|
thrombopoietin - genetics |
1 |
|
thrombosis - drug therapy - etiology - therapy |
1 |
|
thrombotic microangiopathy |
1 |
|
thymidine kinase - genetics |
1 |
|
toes |
1 |
|
tongue |
1 |
|
tongue neoplasms - etiology - surgery |
1 |
|
tonsillectomy |
1 |
|
transcription factors |
1 |
|
transcription factors - drug effects - metabolism |
1 |
|
transient myeloproliferative disease |
1 |
|
transplantation chimera - blood |
1 |
|
tretinoin - administration & dosage - adverse effects |
1 |
|
tretinoin - chemistry - pharmacology |
1 |
|
trisomy 8 |
1 |
|
trk |
1 |
|
tumor markers, biological - analysis - genetics |
1 |
|
tumor suppressor protein p53 - metabolism |
1 |
|
tyrosine 3-monooxygenase - metabolism |
1 |
|
tyrosine hydroxylase |
1 |
|
tyrosine kinase inhibitors |
1 |
|
unnecessary procedures |
1 |
|
valine - genetics - metabolism |
1 |
|
vidarabine - administration & dosage - adverse effects - analogs & derivatives - therapeutic use |
1 |
|
vincristine - therapeutic use |
1 |
|
waldenstrom macroglobulinemia - genetics |
1 |
|
x-rays - adverse effects |
1 |
